Free CME from PeerView

Continuing Nursing Education (CNE) Activities

Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares
StartThis activity expired on September 13, 2024; credit is no longer available.
Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares
Media: Enduring Material
Activity Release Date: September 14, 2023
Activity Expiration Date: September 13, 2024
Time to Complete Activity: 60 minutes
Activity Description
How much do you know about the changing therapeutic landscape and the first FDA-approved treatment for generalized pustular psoriasis (GPP)? Test your knowledge and earn credit as you get the latest evidence and expert guidance on individualizing treatment plans for patients with GPP.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, emergency medicine specialists, general practitioners, family physicians, NPs, PAs, pharmacists, and other healthcare professionals involved in the care of patients with generalized pustular psoriasis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Accurately diagnose pustular psoriasis and assess the disease severity based on patient history and clinical manifestations
- Identify pathophysiological differences among generalized pustular psoriasis (GPP) and plaque psoriasis
- Evaluate novel biologic therapies for pustular psoriasis based on their efficacy, safety, and mechanism of action
- Develop effective, individualized treatment strategies for patients with GPP through patient education and shared decision-making and a multidisciplinary team-based approach
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Faculty/Planner
Boni Elizabeth Elewski, MD
Professor and Chair of Dermatology
UAB/ The University of Alabama at Birmingham
Birmingham, Alabama
Boni Elizabeth Elewski, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Arcutis
Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals,
Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; LEO
Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho
Dermatology; and UCB, Inc.
Grant/Research Support from AbbVie Inc.; AnaptysBio,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.;
Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and UCB,
Inc.
Honoraria from Amgen Inc.; Arcutis Biotherapeutics,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.;
Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatology; and UCB,
Inc.
Faculty/Planner
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Professor & Chair Emeritus
Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine
New York, New York
Mark Lebwohl, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AnaptysBio, Inc.; Almirall, LLC;
AltruBio; AnaptysBio, Inc.; Apogee Therapeutics; Arcutis Biotherapeutics,
Inc.; Aristea Therapeutics; Atomwise Inc.; Avotres Inc.; Boehringer
Ingelheim Pharmaceuticals, Inc.; Brickell Biotech; Bristol Myers Squibb; Cara
Therapeutics; Castle Biosciences, Inc.; Celltrion, Inc.; CorEvitas,
LLC; Dermavant Sciences, Inc.; Dr.Reddy’s; EPI Health; Evommune, Inc.;
Facilitation of International Dermatology Education; Forte Biosciences,
Inc.; Foundation for Research and Education in Dermatology; Galderma;
Genentech, Inc.; Helsinn Healthcare S.A.; Incyte; LEO Pharma Inc.; Meiji
Seika Kaisha, Ltd.; Mindera Health; National Society of Cutaneous
Medicine; Pfizer; Seanergy Dermatology Ltd; Strata; Trevi
Therapeutics; Verrica Pharmaceuticals; and Vial.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Arcutis
Biotherapeutics, Inc.; Avotres Inc.; Boehringer Ingelheim
Pharmaceuticals, Inc.; Cara Therapeutics; Dermavant Sciences,
Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Ortho
Dermatologics; Regeneron Pharmaceuticals Inc.; and UCB,
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-055-H01-P
Type of Activity: Knowledge
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 9/13/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on September 13, 2024; credit is no longer available.
Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares
Media: Enduring Material
Activity Release Date: September 14, 2023
Activity Expiration Date: September 13, 2024
Time to Complete Activity: 60 minutes
Activity Description
How much do you know about the changing therapeutic landscape and the first FDA-approved treatment for generalized pustular psoriasis (GPP)? Test your knowledge and earn credit as you get the latest evidence and expert guidance on individualizing treatment plans for patients with GPP.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, emergency medicine specialists, general practitioners, family physicians, NPs, PAs, pharmacists, and other healthcare professionals involved in the care of patients with generalized pustular psoriasis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Accurately diagnose pustular psoriasis and assess the disease severity based on patient history and clinical manifestations
- Identify pathophysiological differences among generalized pustular psoriasis (GPP) and plaque psoriasis
- Evaluate novel biologic therapies for pustular psoriasis based on their efficacy, safety, and mechanism of action
- Develop effective, individualized treatment strategies for patients with GPP through patient education and shared decision-making and a multidisciplinary team-based approach
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Faculty/Planner
Boni Elizabeth Elewski, MD
Professor and Chair of Dermatology
UAB/ The University of Alabama at Birmingham
Birmingham, Alabama
Boni Elizabeth Elewski, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Arcutis
Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals,
Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; LEO
Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho
Dermatology; and UCB, Inc.
Grant/Research Support from AbbVie Inc.; AnaptysBio,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.;
Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and UCB,
Inc.
Honoraria from Amgen Inc.; Arcutis Biotherapeutics,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.;
Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatology; and UCB,
Inc.
Faculty/Planner
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Professor & Chair Emeritus
Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine
New York, New York
Mark Lebwohl, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AnaptysBio, Inc.; Almirall, LLC;
AltruBio; AnaptysBio, Inc.; Apogee Therapeutics; Arcutis Biotherapeutics,
Inc.; Aristea Therapeutics; Atomwise Inc.; Avotres Inc.; Boehringer
Ingelheim Pharmaceuticals, Inc.; Brickell Biotech; Bristol Myers Squibb; Cara
Therapeutics; Castle Biosciences, Inc.; Celltrion, Inc.; CorEvitas,
LLC; Dermavant Sciences, Inc.; Dr.Reddy’s; EPI Health; Evommune, Inc.;
Facilitation of International Dermatology Education; Forte Biosciences,
Inc.; Foundation for Research and Education in Dermatology; Galderma;
Genentech, Inc.; Helsinn Healthcare S.A.; Incyte; LEO Pharma Inc.; Meiji
Seika Kaisha, Ltd.; Mindera Health; National Society of Cutaneous
Medicine; Pfizer; Seanergy Dermatology Ltd; Strata; Trevi
Therapeutics; Verrica Pharmaceuticals; and Vial.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Arcutis
Biotherapeutics, Inc.; Avotres Inc.; Boehringer Ingelheim
Pharmaceuticals, Inc.; Cara Therapeutics; Dermavant Sciences,
Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Ortho
Dermatologics; Regeneron Pharmaceuticals Inc.; and UCB,
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-055-H01-P
Type of Activity: Knowledge
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 9/13/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy
StartThis activity expired on October 6, 2024; credit is no longer available.
The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other team-based clinicians involved in the management of MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting
- Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS
- Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes
- Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through educational grants from Bristol Myers Squibb, Geron, and Novartis Pharmaceuticals Corporation.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-088-H01-P
Type of Activity: Knowledge
Faculty Disclosures
Co-Chair/Planner
Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
Amy E. DeZern, MD, MHS
Professor of Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Amy E. DeZern, MD, MHS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Caribou
Biosciences; Geron; Gilead Sciences, Inc.; Novartis Pharmaceuticals
Corporation; Regeneron Pharmaceuticals; and Sobi.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 6, 2024; credit is no longer available.
The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other team-based clinicians involved in the management of MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting
- Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS
- Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes
- Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through educational grants from Bristol Myers Squibb, Geron, and Novartis Pharmaceuticals Corporation.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-088-H01-P
Type of Activity: Knowledge
Faculty Disclosures
Co-Chair/Planner
Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
Amy E. DeZern, MD, MHS
Professor of Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Amy E. DeZern, MD, MHS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Caribou
Biosciences; Geron; Gilead Sciences, Inc.; Novartis Pharmaceuticals
Corporation; Regeneron Pharmaceuticals; and Sobi.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Targeting Interleukins to Improve Treatment Outcomes in Atopic Dermatitis
StartThis activity expired on September 24, 2024; credit is no longer available.
Targeting Interleukins to Improve Treatment Outcomes in Atopic Dermatitis
Media: Enduring Material
Activity Release Date: August 25, 2023
Activity Expiration Date: September 24, 2024
Time to Complete Activity: 30 minutes
Activity Description
Atopic dermatitis (AD) is a chronic disease that affects a significant
portion of the US population. The current treatment paradigm for AD is
complex, involving multiple active drugs tailored to different body parts,
stages of the disease, and severity levels, in addition to moisturizers,
bathing practices, and lifestyle recommendations. However, the effectiveness
of certain available treatment options is limited because of concerns
regarding efficacy, tolerability, and safety. In recent years, there have
been significant advancements in the treatment of AD, including the approval
of the first biologic agent and the ongoing clinical development of targeted
therapies.
In this activity, a panel of experts discuss the severity of AD across
different patient populations, considering the chronic and heterogeneous
nature of the disease, and the underlying pathophysiologic processes that
contribute to the development of AD. In addition, they explore
individualizing treatment for patients with moderate to severe AD, with a
goal of minimizing and preventing flares.
Target Audience
This activity has been designed to meet the educational needs of dermatology nurse practitioners and physician assistants and other healthcare professionals involved in the care of patients with atopic dermatitis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Diagnose the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease
- Describe underlying pathophysiologic processes that contribute to the development of AD, and provide rationale for the use of targeted biologic therapy
- Select appropriate treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb;
Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly;
Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi;
Sun Pharmaceutical Industries Limited; and UCB, Inc.
Speaker for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Dermavant
Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Novartis
Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Sun
Pharmaceutical Industries Limited; and UCB, Inc.
Co-Chair/Planner
Peter A. Lio, MD
Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director, Chicago Integrative Eczema Center
Chicago, Illinois
Peter A. Lio, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris,
Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt’s
Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.;
Galderma S.A.; Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Merck & Co., Inc.;
Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals
Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals.
Grant/Research Support from AbbVie Inc. and Regeneron
Pharmaceuticals Inc./Sanofi Genzyme.
Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte;
Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Pfizer; and Regeneron
Pharmaceuticals Inc./Sanofi Genzyme.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
![]() |
This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.25 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23086287. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 9/24/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/CE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on September 24, 2024; credit is no longer available.
Targeting Interleukins to Improve Treatment Outcomes in Atopic Dermatitis
Media: Enduring Material
Activity Release Date: August 25, 2023
Activity Expiration Date: September 24, 2024
Time to Complete Activity: 30 minutes
Activity Description
Atopic dermatitis (AD) is a chronic disease that affects a significant
portion of the US population. The current treatment paradigm for AD is
complex, involving multiple active drugs tailored to different body parts,
stages of the disease, and severity levels, in addition to moisturizers,
bathing practices, and lifestyle recommendations. However, the effectiveness
of certain available treatment options is limited because of concerns
regarding efficacy, tolerability, and safety. In recent years, there have
been significant advancements in the treatment of AD, including the approval
of the first biologic agent and the ongoing clinical development of targeted
therapies.
In this activity, a panel of experts discuss the severity of AD across
different patient populations, considering the chronic and heterogeneous
nature of the disease, and the underlying pathophysiologic processes that
contribute to the development of AD. In addition, they explore
individualizing treatment for patients with moderate to severe AD, with a
goal of minimizing and preventing flares.
Target Audience
This activity has been designed to meet the educational needs of dermatology nurse practitioners and physician assistants and other healthcare professionals involved in the care of patients with atopic dermatitis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Diagnose the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease
- Describe underlying pathophysiologic processes that contribute to the development of AD, and provide rationale for the use of targeted biologic therapy
- Select appropriate treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb;
Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly;
Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi;
Sun Pharmaceutical Industries Limited; and UCB, Inc.
Speaker for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Dermavant
Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Novartis
Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Sun
Pharmaceutical Industries Limited; and UCB, Inc.
Co-Chair/Planner
Peter A. Lio, MD
Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director, Chicago Integrative Eczema Center
Chicago, Illinois
Peter A. Lio, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris,
Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt’s
Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.;
Galderma S.A.; Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Merck & Co., Inc.;
Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals
Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals.
Grant/Research Support from AbbVie Inc. and Regeneron
Pharmaceuticals Inc./Sanofi Genzyme.
Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte;
Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Pfizer; and Regeneron
Pharmaceuticals Inc./Sanofi Genzyme.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
![]() |
This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.25 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23086287. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 9/24/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/CE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Now Is the Time to Overcome Therapeutic Inertia in T2D to Achieve Personalized Glycemic and Weight Management Goals
StartThis activity expired on August 23, 2024; credit is no longer available.
Now Is the Time to Overcome Therapeutic Inertia in T2D to Achieve Personalized Glycemic and Weight Management Goals
Activity Description and Educational Objectives
Type 2 diabetes (T2D) is a progressive disease that is largely preventable and entirely treatable. Timely intensification of therapy is a foundational principle of contemporary management of people with T2D since this strategy is associated with better long-term health outcomes. In conjunction with intensified therapy, modest weight loss has been shown to improve overall and long-term health outcomes. In this activity, based on a series of Project ECHO® workshops and produced in collaboration with the American College of Diabetology, you’ll learn best practices for individualizing patient care and intensifying therapy with evidence-based pharmacologic management of T2D with non-insulin glucose-lowering therapies. Now is the time! Watch today to begin adding these practical strategies to your toolbox!
Upon completion of this activity, participants should be better able to:
- Intensify treatment in people with T2D consistent with the latest guidelines, available evidence, and shared decision-making principles to control glycemia and weight to optimize outcomes and avoid long-term complications
- Explain the rationale for targeting weight and establish personalized weight loss goals as a treatment priority for comprehensive T2D management
- Counsel people with T2D about the relationship between obesity and diabetes and the importance of achieving and maintaining a healthy weight as a T2D treatment priority
Target Audience
This activity has been designed to meet the educational needs of primary care physicians, nurse practitioners (NPs), physician assistants (PAs), and other healthcare professionals involved in the care of patients with type 2 diabetes.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. There are no prerequisites and
there is no fee to participate in this activity or to receive CME/NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Media: Enduring Material
Release and Expiration Dates: August 24, 2023 - August 23, 2024
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.
Co-Chairs & Presenters
Kara Mayes, MD, FAAFP
Medical Director
Mercy Clinic Weight and Wellness
Ballwin, Missouri
Kara Mayes, MD, FAAFP, has no financial interests/relationships or affiliations in relation to this activity.
Jay H. Shubrook, DO, FAAFP, FACOFP
Professor, Primary Care Department
Director of Clinical Research
Director of Diabetes Services
Touro University California
Vallejo, California
Jay H. Shubrook, DO, FAAFP, FACOFP, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Abbott; AstraZeneca; Bayer HealthCare
Pharmaceuticals Inc.; Lilly; Nevro Corp.; and Novo Nordisk Inc.
Other PVI staff who may potentially review content for this activity have
disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development
and review of this activity have disclosed no relevant financial
relationships.
All of the relevant financial relationships listed for these individuals have
been mitigated.
Accreditation, Credit, and Support
Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and the American College of Diabetology.
Physicians
The Penn State College of Medicine designates this enduring material for a
maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Information about CME credit for this activity is available by contacting
Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference
course # G6951-23-T.
Support
This activity is supported by an educational grant from Lilly.
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/NCPD Activity
PVI, PeerView Institute for Medical Education, and Penn State College of
Medicine are responsible for the selection of this activity’s topics, the
preparation of editorial content, and the distribution of this activity. Our
activities may contain references to unapproved products or uses of these
products in certain jurisdictions. The preparation of PeerView activities is
supported by educational grants subject to written agreements that clearly
stipulate and enforce the editorial independence of PVI and Penn State
College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on August 23, 2024; credit is no longer available.
Now Is the Time to Overcome Therapeutic Inertia in T2D to Achieve Personalized Glycemic and Weight Management Goals
Activity Description and Educational Objectives
Type 2 diabetes (T2D) is a progressive disease that is largely preventable and entirely treatable. Timely intensification of therapy is a foundational principle of contemporary management of people with T2D since this strategy is associated with better long-term health outcomes. In conjunction with intensified therapy, modest weight loss has been shown to improve overall and long-term health outcomes. In this activity, based on a series of Project ECHO® workshops and produced in collaboration with the American College of Diabetology, you’ll learn best practices for individualizing patient care and intensifying therapy with evidence-based pharmacologic management of T2D with non-insulin glucose-lowering therapies. Now is the time! Watch today to begin adding these practical strategies to your toolbox!
Upon completion of this activity, participants should be better able to:
- Intensify treatment in people with T2D consistent with the latest guidelines, available evidence, and shared decision-making principles to control glycemia and weight to optimize outcomes and avoid long-term complications
- Explain the rationale for targeting weight and establish personalized weight loss goals as a treatment priority for comprehensive T2D management
- Counsel people with T2D about the relationship between obesity and diabetes and the importance of achieving and maintaining a healthy weight as a T2D treatment priority
Target Audience
This activity has been designed to meet the educational needs of primary care physicians, nurse practitioners (NPs), physician assistants (PAs), and other healthcare professionals involved in the care of patients with type 2 diabetes.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. There are no prerequisites and
there is no fee to participate in this activity or to receive CME/NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Media: Enduring Material
Release and Expiration Dates: August 24, 2023 - August 23, 2024
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.
Co-Chairs & Presenters
Kara Mayes, MD, FAAFP
Medical Director
Mercy Clinic Weight and Wellness
Ballwin, Missouri
Kara Mayes, MD, FAAFP, has no financial interests/relationships or affiliations in relation to this activity.
Jay H. Shubrook, DO, FAAFP, FACOFP
Professor, Primary Care Department
Director of Clinical Research
Director of Diabetes Services
Touro University California
Vallejo, California
Jay H. Shubrook, DO, FAAFP, FACOFP, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Abbott; AstraZeneca; Bayer HealthCare
Pharmaceuticals Inc.; Lilly; Nevro Corp.; and Novo Nordisk Inc.
Other PVI staff who may potentially review content for this activity have
disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development
and review of this activity have disclosed no relevant financial
relationships.
All of the relevant financial relationships listed for these individuals have
been mitigated.
Accreditation, Credit, and Support
Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and the American College of Diabetology.
Physicians
The Penn State College of Medicine designates this enduring material for a
maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Information about CME credit for this activity is available by contacting
Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference
course # G6951-23-T.
Support
This activity is supported by an educational grant from Lilly.
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/NCPD Activity
PVI, PeerView Institute for Medical Education, and Penn State College of
Medicine are responsible for the selection of this activity’s topics, the
preparation of editorial content, and the distribution of this activity. Our
activities may contain references to unapproved products or uses of these
products in certain jurisdictions. The preparation of PeerView activities is
supported by educational grants subject to written agreements that clearly
stipulate and enforce the editorial independence of PVI and Penn State
College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Selective, Potent, Different: How to Enhance Clinical Benefits With Next-Generation ROS1 and TRK Inhibition in Treatment-Naïve and Pretreated NSCLC and Other Tumors
StartThis activity expired on August 8, 2024; credit is no longer available.
Selective, Potent, Different: How to Enhance Clinical Benefits With Next-Generation ROS1 and TRK Inhibition in Treatment-Naïve and Pretreated NSCLC and Other Tumors
Media: Enduring Material
Activity Release Date: August 9, 2023
Activity Expiration Date: August 8, 2024
Time to Complete Activity: 60 minutes
Activity Description
In this activity, an expert in oncology discusses the latest advances with next-generation ROS1 and TRK inhibitors in treatment-naïve and pretreated ROS1 or NTRK fusion–positive NSCLC and other tumors, and provides practical, case-based guidance on how to incorporate these agents into management plans in the context of clinical practice and ongoing trials.
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, nurses, advanced practice clinicians, and other healthcare professionals involved in the care of patients with NSCLC and other solid tumors.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the structure, characteristics, and mechanisms of action of novel tyrosine kinase inhibitors (TKIs) and their role in the treatment of ROS1/NTRK fusion–positive NSCLC and other solid tumors
- Implement best practices for biomarker testing to identify patients with ROS1/NTRK fusion–positive NSCLC or other solid tumors who might benefit from novel TKIs
- Select optimal therapy for individual patients with newly-diagnosed or TKI-resistant ROS1/NTRK fusion–positive NSCLC or other solid tumors in the context of clinical practice or clinical trial participation
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center (MSK)
New York, New York
Alexander Drilon, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for 14ner/Elevation Oncology; AbbVie;
Amgen; ArcherDX, Inc.; AstraZeneca; BeiGene; BerGenBio ASA; Blueprint
Medicines Corporation; Chugai Pharmaceutical Co., Ltd.; EcoR1; EMD Serono;
Entos, Inc.; Exelixis, Inc.; Helsinn Healthcare SA; Hengrui Therapeutics,
Inc.; Ignyta/Genentech, Inc./F. Hoffmann-La Roche, Ltd.; Janssen
Pharmaceuticals, Inc.; Loxo Oncology/Bayer Corporation/Eli Lilly and Company;
Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; Novartis
Pharmaceuticals Corporation; Nuvalent; Pfizer; Prelude Therapeutics; Repare
Therapeutics; Takeda Pharmaceutical Company Limited/ARIAD Pharmaceuticals,
Inc./Millennium Pharmaceuticals, Inc.; Treeline Biosciences, Inc.; Turning
Point Therapeutics; and Tyra Biosciences, Inc.
Grant/Research Support from Foundation Medicine, Inc. *Grant Support
paid to Institution: Exelixis, Inc.; GlaxoSmithKline; Pfizer; PharmaMar;
Taiho Oncology, Inc; and Teva Pharmaceuticals USA, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 8/8/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on August 8, 2024; credit is no longer available.
Selective, Potent, Different: How to Enhance Clinical Benefits With Next-Generation ROS1 and TRK Inhibition in Treatment-Naïve and Pretreated NSCLC and Other Tumors
Media: Enduring Material
Activity Release Date: August 9, 2023
Activity Expiration Date: August 8, 2024
Time to Complete Activity: 60 minutes
Activity Description
In this activity, an expert in oncology discusses the latest advances with next-generation ROS1 and TRK inhibitors in treatment-naïve and pretreated ROS1 or NTRK fusion–positive NSCLC and other tumors, and provides practical, case-based guidance on how to incorporate these agents into management plans in the context of clinical practice and ongoing trials.
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, nurses, advanced practice clinicians, and other healthcare professionals involved in the care of patients with NSCLC and other solid tumors.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the structure, characteristics, and mechanisms of action of novel tyrosine kinase inhibitors (TKIs) and their role in the treatment of ROS1/NTRK fusion–positive NSCLC and other solid tumors
- Implement best practices for biomarker testing to identify patients with ROS1/NTRK fusion–positive NSCLC or other solid tumors who might benefit from novel TKIs
- Select optimal therapy for individual patients with newly-diagnosed or TKI-resistant ROS1/NTRK fusion–positive NSCLC or other solid tumors in the context of clinical practice or clinical trial participation
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center (MSK)
New York, New York
Alexander Drilon, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for 14ner/Elevation Oncology; AbbVie;
Amgen; ArcherDX, Inc.; AstraZeneca; BeiGene; BerGenBio ASA; Blueprint
Medicines Corporation; Chugai Pharmaceutical Co., Ltd.; EcoR1; EMD Serono;
Entos, Inc.; Exelixis, Inc.; Helsinn Healthcare SA; Hengrui Therapeutics,
Inc.; Ignyta/Genentech, Inc./F. Hoffmann-La Roche, Ltd.; Janssen
Pharmaceuticals, Inc.; Loxo Oncology/Bayer Corporation/Eli Lilly and Company;
Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; Novartis
Pharmaceuticals Corporation; Nuvalent; Pfizer; Prelude Therapeutics; Repare
Therapeutics; Takeda Pharmaceutical Company Limited/ARIAD Pharmaceuticals,
Inc./Millennium Pharmaceuticals, Inc.; Treeline Biosciences, Inc.; Turning
Point Therapeutics; and Tyra Biosciences, Inc.
Grant/Research Support from Foundation Medicine, Inc. *Grant Support
paid to Institution: Exelixis, Inc.; GlaxoSmithKline; Pfizer; PharmaMar;
Taiho Oncology, Inc; and Teva Pharmaceuticals USA, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 8/8/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Road Map to Re-Engagement: A Visual Guide to Overcoming Individual and Systemic Barriers to HIV Care and Treatment
StartThis activity expired on August 2, 2024; credit is no longer available.
Road Map to Re-Engagement: A Visual Guide to Overcoming Individual and Systemic Barriers to HIV Care and Treatment
Media: Enduring Material
Activity Release Date: August 3, 2023
Activity Expiration Date: August 2, 2024
Time to Complete Activity:
- 45 minutes
Activity Description
In this activity, an expert discusses the factors that contribute to people living with HIV (PLWH) falling out of care, the barriers associated with different strategies for re-engaging PLWH, and individualized plans that can be used for re-engaging PLWH back into care.
Target Audience
This activity has been designed to meet the educational needs of primary care providers, HIV care providers, infectious disease providers, HIV workforce professionals, and other clinicians involved in the care of patients with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify individual and structural factors that contribute to PLWH falling out of care
- Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
- Employ individualized and comprehensive plans to successfully re-engage PLWH in care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Babafemi O. Taiwo, MBBS
Chief of Infectious Diseases in the Department of Medicine
Gene Stollerman Professor of Medicine
Professor of Medicine (Infectious Diseases)
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Babafemi O. Taiwo, MBBS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Johnson &
Johnson; Merck & Co., Inc.; and ViiV Healthcare.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Partners
This activity has been developed in partnership with HealthHIV
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-047-H02-P
Type of Activity:
Health Education Specialists
Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/CECH Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on August 2, 2024; credit is no longer available.
Road Map to Re-Engagement: A Visual Guide to Overcoming Individual and Systemic Barriers to HIV Care and Treatment
Media: Enduring Material
Activity Release Date: August 3, 2023
Activity Expiration Date: August 2, 2024
Time to Complete Activity:
- 45 minutes
Activity Description
In this activity, an expert discusses the factors that contribute to people living with HIV (PLWH) falling out of care, the barriers associated with different strategies for re-engaging PLWH, and individualized plans that can be used for re-engaging PLWH back into care.
Target Audience
This activity has been designed to meet the educational needs of primary care providers, HIV care providers, infectious disease providers, HIV workforce professionals, and other clinicians involved in the care of patients with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify individual and structural factors that contribute to PLWH falling out of care
- Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
- Employ individualized and comprehensive plans to successfully re-engage PLWH in care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Babafemi O. Taiwo, MBBS
Chief of Infectious Diseases in the Department of Medicine
Gene Stollerman Professor of Medicine
Professor of Medicine (Infectious Diseases)
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Babafemi O. Taiwo, MBBS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Johnson &
Johnson; Merck & Co., Inc.; and ViiV Healthcare.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Partners
This activity has been developed in partnership with HealthHIV
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-047-H02-P
Type of Activity:
Health Education Specialists
Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/CECH Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy
StartThis activity expired on August 1, 2024; credit is no longer available.
Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy
Media: Enduring Material
Activity Release Date: August 2, 2023
Activity Expiration Date: August 1, 2024
Time to Complete Activity: 60 minutes
Activity Description
Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care.
Target Audience
This activity has been designed to meet the educational needs of hematologists, oncologists, hematology-oncologists, pathologists, nurses, pharmacists, and other clinicians involved in the care of patients with CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
- Cite validated techniques, including next-generation sequencing, to identify prognostic and predictive markers such as del(17p)/TP53, BTK mutations, and minimal residual disease status to inform treatment decisions
- Develop team-based management strategies that include patient treatment history, prognostic information, and other clinically relevant factors
- Implement team-based strategies to educate patients on their prognosis, facilitate clinical trial enrollment, and address dosing and safety considerations when using BTKi strategies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Jennifer Woyach, MD
Professor of Internal Medicine
Division of Hematology
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research
Institute
Columbus, Ohio
Jennifer Woyach, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene;
Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave
Pharmaceutical Inc; and Pharmacyclics LLC.
Grant/Research Support from AstraZeneca; Karyopharm Therapeutics;
Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.;
Schrödinger, Inc.; and Verastem Oncology.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
![]() |
The activity titled “Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-054-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on August 1, 2024; credit is no longer available.
Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy
Media: Enduring Material
Activity Release Date: August 2, 2023
Activity Expiration Date: August 1, 2024
Time to Complete Activity: 60 minutes
Activity Description
Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care.
Target Audience
This activity has been designed to meet the educational needs of hematologists, oncologists, hematology-oncologists, pathologists, nurses, pharmacists, and other clinicians involved in the care of patients with CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
- Cite validated techniques, including next-generation sequencing, to identify prognostic and predictive markers such as del(17p)/TP53, BTK mutations, and minimal residual disease status to inform treatment decisions
- Develop team-based management strategies that include patient treatment history, prognostic information, and other clinically relevant factors
- Implement team-based strategies to educate patients on their prognosis, facilitate clinical trial enrollment, and address dosing and safety considerations when using BTKi strategies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Jennifer Woyach, MD
Professor of Internal Medicine
Division of Hematology
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research
Institute
Columbus, Ohio
Jennifer Woyach, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene;
Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave
Pharmaceutical Inc; and Pharmacyclics LLC.
Grant/Research Support from AstraZeneca; Karyopharm Therapeutics;
Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.;
Schrödinger, Inc.; and Verastem Oncology.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
![]() |
The activity titled “Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-054-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Redefining Balance in Hemophilia: Can We Restore Hemostasis by Inhibiting Anticoagulation?
StartCE Details
Redefining Balance in Hemophilia: Can We Restore Hemostasis by Inhibiting Anticoagulation?
PeerVoice is an EBAC® accredited provider since 2022.
Accreditation
This programme is accredited by the European Board for Accreditation of
Continuing Education for Health Professionals (EBAC®) for up to 1.0
hour(s) of external CE credit(s). Each participant should claim only
time that has been spent in the educational activity.
The Accreditation Council for Continuing Medical Education (ACCME®), and the
Royal College of Physicians and Surgeons of Canada hold an agreement on
substantial equivalency of accreditation systems with EBAC®.
Through an agreement between the European Board for Accreditation of
Continuing Education for Health Professionals and the American Medical
Association (AMA), physicians may convert EBAC® CE credits to AMA PRA
Category 1 CreditsTM. Information on the process to convert
EBAC® credit to AMA credit can be found on the AMA website. Other health care
professionals may obtain from the AMA a certificate of having participated in
an activity eligible for conversion of credit to AMA PRA Category 1
CreditTM.
Activity Description and Educational Objectives
In this activity, based on a recent live event, hemophilia experts discuss the coagulation cascade, the rationale to restore hemostasis by inhibiting natural anticoagulants, and the mechanism of action and available evidence for emerging investigational therapies.
Upon completion of this activity, participants should be better able to:
- Identify elements of the coagulation cascade that are targets of current hemophilia treatments, including factor replacement therapies and factor mimetics
- Recognize the mechanism of action of rebalancing therapies under investigation for the management of hemophilia, including small-interference RNA (siRNA) therapies and tissue factor pathway inhibitors (TFPIs)
- Assess the clinical relevance of safety and efficacy data from trials evaluating rebalancing therapies for the treatment of hemophilia A and/or B, including the patient profiles of those included in these trials
Target Audience
This activity has been designed to meet the educational needs of hematologists and other clinicians involved in the management of patients with hemophilia.
Faculty Disclosure Statement / Conflict of Interest Policy
In compliance with EBAC® guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CE activities.
Course Director

Johnny Mahlangu, MBBCH, MMed, FCPath, has a financial
interest/relationship or affiliation in the form of:
Consultant for BioMarin Pharmaceutical Inc.; F. Hoffmann-La Roche
Ltd; Novo Nordisk A/S; Sanofi; Spark Therapeutics, Inc.; and Takeda
Pharmaceutical Company Limited.
Grant/Research Support from BioMarin Pharmaceutical Inc.; F.
Hoffmann-La Roche Ltd; Novartis AG; Novo Nordisk A/S; Pfizer Inc.; Sanofi;
Spark Therapeutics, Inc.; and uniQure N.V.
Speakers Bureau participant with BioMarin Pharmaceutical Inc.; F.
Hoffmann-La Roche Ltd; Novo Nordisk A/S; Pfizer Inc.; Sanofi; and Takeda
Pharmaceutical Company Limited.
Advisory Board for BioMarin Pharmaceutical Inc.; F. Hoffmann-La
Roche Ltd; Novo Nordisk A/S; Sanofi; Spark Therapeutics, Inc.; and Takeda
Pharmaceutical Company Limited.
Faculty

Laurent Frenzel, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant for BioMarin Pharmaceutical Inc.; F. Hoffmann-La Roche
Ltd; and Novo Nordisk A/S.
Grant/Research Support from CSL Behring and Pfizer Inc.
Faculty

Christopher E. Walsh, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Advisory Board for BioMarin Pharmaceutical Inc.; Genentech, Inc.;
Novo Nordisk A/S; and Sanofi.
PeerVoice Medical Director
Anna Bartus, MD, has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
To receive credit, participants must complete the activity, the post-test,
and the evaluation form prior to the expiration date noted below. There are
no pre-requisites and there is no fee to participate in this activity or to
receive credit. Certificates of Completion may be awarded upon successful
completion of the post-test and evaluation form. Consult your professional
licensing board for information about your eligibility to claim credit for
participation in this educational activity. A minimum performance level of
70% is needed.
Please note that EBAC® only awards CE certificates in
increments of 1.0 credit, therefore this activity will need to be submitted
with other joint-provided activities from PeerVoice in order to redeem EBAC®
credit.
Media: Enduring Material
Release and Expiration Dates: 10 July 2023 – 9 July 2025
Time to Complete: 45 minutes
Funding Disclosure
This activity is supported by an educational grant from Sanofi.
Disclosure of Unlabelled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labelled for use in certain
jurisdictions. Faculty members have been advised to disclose to the audience
any reference to an unlabelled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our materials. No responsibility is taken for
errors or omissions in our materials.
Please refer to the official prescribing information for each product for
discussion of approved indications, contraindications, and warnings.
Disclaimer
The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerVoice or any of its supporters.
The information provided in this activity has been confirmed as medically accurate at date of publication.

CE Details
Redefining Balance in Hemophilia: Can We Restore Hemostasis by Inhibiting Anticoagulation?
PeerVoice is an EBAC® accredited provider since 2022.
Accreditation
This programme is accredited by the European Board for Accreditation of
Continuing Education for Health Professionals (EBAC®) for up to 1.0
hour(s) of external CE credit(s). Each participant should claim only
time that has been spent in the educational activity.
The Accreditation Council for Continuing Medical Education (ACCME®), and the
Royal College of Physicians and Surgeons of Canada hold an agreement on
substantial equivalency of accreditation systems with EBAC®.
Through an agreement between the European Board for Accreditation of
Continuing Education for Health Professionals and the American Medical
Association (AMA), physicians may convert EBAC® CE credits to AMA PRA
Category 1 CreditsTM. Information on the process to convert
EBAC® credit to AMA credit can be found on the AMA website. Other health care
professionals may obtain from the AMA a certificate of having participated in
an activity eligible for conversion of credit to AMA PRA Category 1
CreditTM.
Activity Description and Educational Objectives
In this activity, based on a recent live event, hemophilia experts discuss the coagulation cascade, the rationale to restore hemostasis by inhibiting natural anticoagulants, and the mechanism of action and available evidence for emerging investigational therapies.
Upon completion of this activity, participants should be better able to:
- Identify elements of the coagulation cascade that are targets of current hemophilia treatments, including factor replacement therapies and factor mimetics
- Recognize the mechanism of action of rebalancing therapies under investigation for the management of hemophilia, including small-interference RNA (siRNA) therapies and tissue factor pathway inhibitors (TFPIs)
- Assess the clinical relevance of safety and efficacy data from trials evaluating rebalancing therapies for the treatment of hemophilia A and/or B, including the patient profiles of those included in these trials
Target Audience
This activity has been designed to meet the educational needs of hematologists and other clinicians involved in the management of patients with hemophilia.
Faculty Disclosure Statement / Conflict of Interest Policy
In compliance with EBAC® guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CE activities.
Course Director

Johnny Mahlangu, MBBCH, MMed, FCPath, has a financial
interest/relationship or affiliation in the form of:
Consultant for BioMarin Pharmaceutical Inc.; F. Hoffmann-La Roche
Ltd; Novo Nordisk A/S; Sanofi; Spark Therapeutics, Inc.; and Takeda
Pharmaceutical Company Limited.
Grant/Research Support from BioMarin Pharmaceutical Inc.; F.
Hoffmann-La Roche Ltd; Novartis AG; Novo Nordisk A/S; Pfizer Inc.; Sanofi;
Spark Therapeutics, Inc.; and uniQure N.V.
Speakers Bureau participant with BioMarin Pharmaceutical Inc.; F.
Hoffmann-La Roche Ltd; Novo Nordisk A/S; Pfizer Inc.; Sanofi; and Takeda
Pharmaceutical Company Limited.
Advisory Board for BioMarin Pharmaceutical Inc.; F. Hoffmann-La
Roche Ltd; Novo Nordisk A/S; Sanofi; Spark Therapeutics, Inc.; and Takeda
Pharmaceutical Company Limited.
Faculty

Laurent Frenzel, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant for BioMarin Pharmaceutical Inc.; F. Hoffmann-La Roche
Ltd; and Novo Nordisk A/S.
Grant/Research Support from CSL Behring and Pfizer Inc.
Faculty

Christopher E. Walsh, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Advisory Board for BioMarin Pharmaceutical Inc.; Genentech, Inc.;
Novo Nordisk A/S; and Sanofi.
PeerVoice Medical Director
Anna Bartus, MD, has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
To receive credit, participants must complete the activity, the post-test,
and the evaluation form prior to the expiration date noted below. There are
no pre-requisites and there is no fee to participate in this activity or to
receive credit. Certificates of Completion may be awarded upon successful
completion of the post-test and evaluation form. Consult your professional
licensing board for information about your eligibility to claim credit for
participation in this educational activity. A minimum performance level of
70% is needed.
Please note that EBAC® only awards CE certificates in
increments of 1.0 credit, therefore this activity will need to be submitted
with other joint-provided activities from PeerVoice in order to redeem EBAC®
credit.
Media: Enduring Material
Release and Expiration Dates: 10 July 2023 – 9 July 2025
Time to Complete: 45 minutes
Funding Disclosure
This activity is supported by an educational grant from Sanofi.
Disclosure of Unlabelled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labelled for use in certain
jurisdictions. Faculty members have been advised to disclose to the audience
any reference to an unlabelled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our materials. No responsibility is taken for
errors or omissions in our materials.
Please refer to the official prescribing information for each product for
discussion of approved indications, contraindications, and warnings.
Disclaimer
The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerVoice or any of its supporters.
The information provided in this activity has been confirmed as medically accurate at date of publication.


The Team Takes Command in MDS: Guidance on Diagnostic and Treatment Principles for Risk-Based Care and Beyond
StartThis activity expired on July 3, 2024; credit is no longer available.
The Team Takes Command in MDS: Guidance on Diagnostic and Treatment Principles for Risk-Based Care and Beyond
Media: Enduring Material
Activity Release Date: June 4, 2023
Activity Expiration Date: July 3, 2024
Time to Complete Activity: 60 minutes
Activity Description
Rapid change is coming to the management of myelodysplastic syndromes
(MDS), fueled by new science that will expand the therapeutic possibilities
for managing different patient populations and impact the management team.
But are you ready to be a team player and help revolutionize MDS care?
Find out by viewing this PeerView “Clinical Consults” activity based on a
symposium held during the 2023 ASCO Annual Meeting. Watch as an expert panel
provides insights on the use of innovative therapies for the first-line
management of MDS anemia, the treatment of ESA-refractory patients, and
management of patients presenting with high-risk disease. Throughout, they
will also provide practical insights for effective delivery of care,
including patient education, appropriate dosing, and adverse event
management. Don’t miss this opportunity to see how your team can take command
of care when managing your patients with MDS!
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologists/oncologists, advanced practice clinicians, and other clinicians involved in the management of MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss molecular and pathologic features, risk factors, and clinical signs that can inform a timely team-based diagnostic and prognostic assessment of MDS
- Cite clinical evidence supporting the use of innovative therapeutics with unique mechanisms of action for the management of patients with low-risk or high-risk MDS
- Develop risk-adapted team management of protocols for patients with MDS, including for the first-line management of anemia, in the ESA-failing setting, or for patients presenting with higher-risk genomic subtypes
- Recommend team-based strategies to manage therapy delivery considerations in the MDS setting, including selection of appropriate dosing, response monitoring, and management of therapy-related adverse events
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.
Faculty/Planner
Rami Komrokji, MD
Vice Chair - Malignant Hematology
Section Head - Leukemia & MDS
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Rami Komrokji, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; CTI
BioPharma; Geron; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals
Corporation; PharmaEssentia; Rigel Pharmaceuticals, Inc.; Servier
Pharmaceuticals; and Taiho Oncology, Inc.
Grant/Research Support from Bristol Myers Squibb.
Speaker for AbbVie; CTI BioPharma; Jazz Pharmaceuticals, Inc.;
PharmaEssentia; and Servier Pharmaceuticals.
Faculty/Planner
Aditi Shastri, MD
Associate Professor, Department of Oncology
Department of Developmental & Molecular Biology
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, New York
Aditi Shastri, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Janssen
Pharmaceuticals, Inc.; Kymera Therapeutics; and Rigel Pharmaceuticals,
Inc.
Grant/Research Support from Kymera Therapeutics.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through educational grants from Astex Pharmaceuticals, Inc., Bristol Myers Squibb, and Geron.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 7/3/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on July 3, 2024; credit is no longer available.
The Team Takes Command in MDS: Guidance on Diagnostic and Treatment Principles for Risk-Based Care and Beyond
Media: Enduring Material
Activity Release Date: June 4, 2023
Activity Expiration Date: July 3, 2024
Time to Complete Activity: 60 minutes
Activity Description
Rapid change is coming to the management of myelodysplastic syndromes
(MDS), fueled by new science that will expand the therapeutic possibilities
for managing different patient populations and impact the management team.
But are you ready to be a team player and help revolutionize MDS care?
Find out by viewing this PeerView “Clinical Consults” activity based on a
symposium held during the 2023 ASCO Annual Meeting. Watch as an expert panel
provides insights on the use of innovative therapies for the first-line
management of MDS anemia, the treatment of ESA-refractory patients, and
management of patients presenting with high-risk disease. Throughout, they
will also provide practical insights for effective delivery of care,
including patient education, appropriate dosing, and adverse event
management. Don’t miss this opportunity to see how your team can take command
of care when managing your patients with MDS!
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologists/oncologists, advanced practice clinicians, and other clinicians involved in the management of MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss molecular and pathologic features, risk factors, and clinical signs that can inform a timely team-based diagnostic and prognostic assessment of MDS
- Cite clinical evidence supporting the use of innovative therapeutics with unique mechanisms of action for the management of patients with low-risk or high-risk MDS
- Develop risk-adapted team management of protocols for patients with MDS, including for the first-line management of anemia, in the ESA-failing setting, or for patients presenting with higher-risk genomic subtypes
- Recommend team-based strategies to manage therapy delivery considerations in the MDS setting, including selection of appropriate dosing, response monitoring, and management of therapy-related adverse events
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.
Faculty/Planner
Rami Komrokji, MD
Vice Chair - Malignant Hematology
Section Head - Leukemia & MDS
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Rami Komrokji, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; CTI
BioPharma; Geron; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals
Corporation; PharmaEssentia; Rigel Pharmaceuticals, Inc.; Servier
Pharmaceuticals; and Taiho Oncology, Inc.
Grant/Research Support from Bristol Myers Squibb.
Speaker for AbbVie; CTI BioPharma; Jazz Pharmaceuticals, Inc.;
PharmaEssentia; and Servier Pharmaceuticals.
Faculty/Planner
Aditi Shastri, MD
Associate Professor, Department of Oncology
Department of Developmental & Molecular Biology
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, New York
Aditi Shastri, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Janssen
Pharmaceuticals, Inc.; Kymera Therapeutics; and Rigel Pharmaceuticals,
Inc.
Grant/Research Support from Kymera Therapeutics.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through educational grants from Astex Pharmaceuticals, Inc., Bristol Myers Squibb, and Geron.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 7/3/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider
StartThis activity expired on June 28, 2024; credit is no longer available.
Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider
Media: Enduring Material
Activity Release Date: June 29, 2023
Activity Expiration Date: June 28, 2024
Time to Complete Activity: 45 minutes
Activity Description
In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum.
Target Audience
This activity has been designed to meet the educational needs of healthcare professionals who treat, care for, and/or support people living with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify individual and structural factors that contribute to PLWH falling out of care
- Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
- Employ individualized and comprehensive plans to successfully re-engage PLWH in care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Allison Agwu, MD, ScM, FAAP, FIDSA
Professor of Pediatrics and Internal Medicine
Division of Infectious Diseases
Program Director, Pediatric Adolescent Young Adult HIV/AIDS Program
Medical Director, Accessing Care Early (ACE) Clinic
Johns Hopkins University School of Medicine
Baltimore, Maryland
Allison Agwu, MD, ScM, FAAP, FIDSA, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Merck & Co.,
Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co.,
Inc.
Faculty/Planner
Nara Lee, LICSW
Social Work & Clinical Services Manager
HIV Prevention and Treatment Services
Special Immunology Services
Children’s National Hospital
Washington, DC
Nara Lee, LICSW, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
David Martin
Patient/Advocate
David Martin has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Shawnte' Spriggs
Patient/Advocate
Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-046-H02-P
Type of Activity: Knowledge
Health Education Specialists
Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/CECH Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on June 28, 2024; credit is no longer available.
Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider
Media: Enduring Material
Activity Release Date: June 29, 2023
Activity Expiration Date: June 28, 2024
Time to Complete Activity: 45 minutes
Activity Description
In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum.
Target Audience
This activity has been designed to meet the educational needs of healthcare professionals who treat, care for, and/or support people living with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify individual and structural factors that contribute to PLWH falling out of care
- Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
- Employ individualized and comprehensive plans to successfully re-engage PLWH in care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Allison Agwu, MD, ScM, FAAP, FIDSA
Professor of Pediatrics and Internal Medicine
Division of Infectious Diseases
Program Director, Pediatric Adolescent Young Adult HIV/AIDS Program
Medical Director, Accessing Care Early (ACE) Clinic
Johns Hopkins University School of Medicine
Baltimore, Maryland
Allison Agwu, MD, ScM, FAAP, FIDSA, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Merck & Co.,
Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co.,
Inc.
Faculty/Planner
Nara Lee, LICSW
Social Work & Clinical Services Manager
HIV Prevention and Treatment Services
Special Immunology Services
Children’s National Hospital
Washington, DC
Nara Lee, LICSW, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
David Martin
Patient/Advocate
David Martin has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Shawnte' Spriggs
Patient/Advocate
Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-046-H02-P
Type of Activity: Knowledge
Health Education Specialists
Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/CECH Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Scoring Comprehensive T2DM Management Goals: Examining the Multifaceted Effects of GLP-1 Receptor Agonists
StartThis activity expired on June 26, 2024; credit is no longer available.
Scoring Comprehensive T2DM Management Goals: Examining the Multifaceted Effects of GLP-1 Receptor Agonists
Media: Enduring Material
Activity Release Date: June 27, 2023
Activity Expiration Date: June 26, 2024
Time to Complete Activity: 60 minutes
Activity Description
Type 2 diabetes mellitus (T2DM) is a worldwide health concern. With more people living longer, the prevalence of chronic comorbid diseases has increased dramatically, and there is a resurgence in diabetic complications. T2DM shares risk factors with atherosclerotic cardiovascular disease (ASCVD), the leading cause of death among patients with T2DM. Furthermore, T2DM is a leading cause of kidney failure. How can clinicians address the underlying pathophysiology and comorbid organ damage that is frequently associated with T2DM? This activity seeks to answer that question using patient cases to examine where GLP-1 receptor agonists (RAs) fit in modern treatment algorithms and help recognize the differences between GLP-1 RA options. Importantly, you’ll also hear practical strategies to help navigate the ins and outs of patient-centered care.
Target Audience
This activity has been designed to meet the educational needs of primary care providers (PCPs) including family practice physicians, nurse practitioners (NPs), physician assistants (PAs), and other healthcare professionals involved in the care of patients with T2DM.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the rationale for using GLP-1 RAs in comprehensive T2DM management plans to optimize patient outcomes and reduce the risk of associated complications
- Compare current and emerging agents targeting GLP-1 based on their mechanisms of action, dosing frequency, efficacy, safety, and tolerability profiles
- Identify patients who would benefit from the multifaceted glycemic and extra-glycemic effects of GLP-1 RAs as part of comprehensive T2DM management plans
- Counsel, as a member of a multidisciplinary care team, patients with T2DM about the long-term efficacy, safety, and convenience that GLP-1 RAs have to offer as a means to achieving individualized glycemic and non-glycemic health goals
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
John B. Buse, MD, PhD
Verne S. Caviness Distinguished Professor
Director, Diabetes Center
Director, NC Translational and Clinical Sciences Institute
Senior Associate Dean, Clinical Research
University of North Carolina School of Medicine
Chapel Hill, North Carolina
John B. Buse, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alkahest, Inc.; Altimmune; Anji
Pharmaceuticals Inc.; AstraZeneca; Bayer Corporation; Biomea Fusion, Inc.;
Boehringer Ingelheim Pharmaceuticals, Inc.; CeQur Simplicity; Cirius
Therapeutics; Corcept; Fortress Biotech, Inc.; GentiBio; Glycadia, Inc.;
Glyscend, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; MannKind Corporation;
Mellitus Health, Inc.; Moderna, Inc.; Novo Nordisk A/S; Pendulum; Praetego,
LLC; sanofi-aventis U.S. LLC; Stability Health; Terns Pharmeceuticals, Inc.;
Valo Therapeutics Ltd; and Zealand Pharma A/S.
Grant/Research Support from Dexcom, Inc.; National Institutes of
Health; NovaTarg Therapeutics; Novo Nordisk A/S; sanofi-aventis U.S. LLC;
Patient-Centered Outcomes Research Institute (PCORI); Tolerion, Inc.; and vTv
Therapeutics.
Stock Shareholder in Glyscend, Inc.; Mellitus Health, Inc.;
Pendulum; PhaseBio Pharmaceuticals, Inc.; Praetego, LLC; and Stability
Health.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Novo Nordisk Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 6/26/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on June 26, 2024; credit is no longer available.
Scoring Comprehensive T2DM Management Goals: Examining the Multifaceted Effects of GLP-1 Receptor Agonists
Media: Enduring Material
Activity Release Date: June 27, 2023
Activity Expiration Date: June 26, 2024
Time to Complete Activity: 60 minutes
Activity Description
Type 2 diabetes mellitus (T2DM) is a worldwide health concern. With more people living longer, the prevalence of chronic comorbid diseases has increased dramatically, and there is a resurgence in diabetic complications. T2DM shares risk factors with atherosclerotic cardiovascular disease (ASCVD), the leading cause of death among patients with T2DM. Furthermore, T2DM is a leading cause of kidney failure. How can clinicians address the underlying pathophysiology and comorbid organ damage that is frequently associated with T2DM? This activity seeks to answer that question using patient cases to examine where GLP-1 receptor agonists (RAs) fit in modern treatment algorithms and help recognize the differences between GLP-1 RA options. Importantly, you’ll also hear practical strategies to help navigate the ins and outs of patient-centered care.
Target Audience
This activity has been designed to meet the educational needs of primary care providers (PCPs) including family practice physicians, nurse practitioners (NPs), physician assistants (PAs), and other healthcare professionals involved in the care of patients with T2DM.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the rationale for using GLP-1 RAs in comprehensive T2DM management plans to optimize patient outcomes and reduce the risk of associated complications
- Compare current and emerging agents targeting GLP-1 based on their mechanisms of action, dosing frequency, efficacy, safety, and tolerability profiles
- Identify patients who would benefit from the multifaceted glycemic and extra-glycemic effects of GLP-1 RAs as part of comprehensive T2DM management plans
- Counsel, as a member of a multidisciplinary care team, patients with T2DM about the long-term efficacy, safety, and convenience that GLP-1 RAs have to offer as a means to achieving individualized glycemic and non-glycemic health goals
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
John B. Buse, MD, PhD
Verne S. Caviness Distinguished Professor
Director, Diabetes Center
Director, NC Translational and Clinical Sciences Institute
Senior Associate Dean, Clinical Research
University of North Carolina School of Medicine
Chapel Hill, North Carolina
John B. Buse, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alkahest, Inc.; Altimmune; Anji
Pharmaceuticals Inc.; AstraZeneca; Bayer Corporation; Biomea Fusion, Inc.;
Boehringer Ingelheim Pharmaceuticals, Inc.; CeQur Simplicity; Cirius
Therapeutics; Corcept; Fortress Biotech, Inc.; GentiBio; Glycadia, Inc.;
Glyscend, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; MannKind Corporation;
Mellitus Health, Inc.; Moderna, Inc.; Novo Nordisk A/S; Pendulum; Praetego,
LLC; sanofi-aventis U.S. LLC; Stability Health; Terns Pharmeceuticals, Inc.;
Valo Therapeutics Ltd; and Zealand Pharma A/S.
Grant/Research Support from Dexcom, Inc.; National Institutes of
Health; NovaTarg Therapeutics; Novo Nordisk A/S; sanofi-aventis U.S. LLC;
Patient-Centered Outcomes Research Institute (PCORI); Tolerion, Inc.; and vTv
Therapeutics.
Stock Shareholder in Glyscend, Inc.; Mellitus Health, Inc.;
Pendulum; PhaseBio Pharmaceuticals, Inc.; Praetego, LLC; and Stability
Health.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Novo Nordisk Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 6/26/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Can We Improve Management of Overactive Bladder in Long-Term Care? Examining the Role of Beta-3 Adrenergic Agonists
StartThis activity expired on June 12, 2024; credit is no longer available.
Can We Improve Management of Overactive Bladder in Long-Term Care? Examining the Role of Beta-3 Adrenergic Agonists
Media: Enduring Material
Activity Release Date: June 13, 2023
Activity Expiration Date: June 12, 2024
Time to Complete Activity: 60 minutes
Activity Description
Overactive bladder is frequently underdiagnosed and undertreated, but
fortunately there's a newer treatment option with the beta-3 adrenoreceptor
agonists. This class demonstrates efficacy without anticholinergic adverse
effects, enabling you to provide optimal, patient-centered care for residents
of long-term care facilities.
This PeerView educational activity is designed to help improve your ability
to accurately recognize overactive bladder, apply appropriate diagnostic
criteria, and incorporate newer treatment options. Expert faculty explain the
clinically relevant ways in which the newer beta-3 adrenoreceptor agonists
differ from traditional antimuscarinics, as well as how they differ from each
other with regard to selectivity and safety.
Target Audience
This activity has been designed to meet the educational needs of geriatricians, urologists, family practitioners, advanced practice clinicians (NPs/PAs), nurses, and other healthcare professionals involved in the care of patients with overactive bladder.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Recognize the individual, clinical, and economic burdens of OAB specific to patients living in long-term care facilities
- Engage members of the healthcare team to routinely screen long-term care residents for symptoms of OAB
- Apply recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomatology
- Implement individualized OAB treatment plans that minimize risks related to cardiovascular health, cognitive impairment and dementia, and polypharmacy concerns
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Benjamin M. Brucker, MD
Director, Division of Female Pelvic Medicine & Reconstructive Surgery and
Neurourology
Program Director, FPMRS Fellowship
Departments of Urology and Obstetrics & Gynecology
New York University
Langone Health
New York, New York
Benjamin M. Brucker, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Palette Life
Sciences, Inc.; Urovant Sciences Inc.; and Watkins-Conti Products.
Speaker for AbbVie Inc.; Antares Pharma, Inc.; and Urovant
Sciences Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Urovant Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 6/12/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on June 12, 2024; credit is no longer available.
Can We Improve Management of Overactive Bladder in Long-Term Care? Examining the Role of Beta-3 Adrenergic Agonists
Media: Enduring Material
Activity Release Date: June 13, 2023
Activity Expiration Date: June 12, 2024
Time to Complete Activity: 60 minutes
Activity Description
Overactive bladder is frequently underdiagnosed and undertreated, but
fortunately there's a newer treatment option with the beta-3 adrenoreceptor
agonists. This class demonstrates efficacy without anticholinergic adverse
effects, enabling you to provide optimal, patient-centered care for residents
of long-term care facilities.
This PeerView educational activity is designed to help improve your ability
to accurately recognize overactive bladder, apply appropriate diagnostic
criteria, and incorporate newer treatment options. Expert faculty explain the
clinically relevant ways in which the newer beta-3 adrenoreceptor agonists
differ from traditional antimuscarinics, as well as how they differ from each
other with regard to selectivity and safety.
Target Audience
This activity has been designed to meet the educational needs of geriatricians, urologists, family practitioners, advanced practice clinicians (NPs/PAs), nurses, and other healthcare professionals involved in the care of patients with overactive bladder.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Recognize the individual, clinical, and economic burdens of OAB specific to patients living in long-term care facilities
- Engage members of the healthcare team to routinely screen long-term care residents for symptoms of OAB
- Apply recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomatology
- Implement individualized OAB treatment plans that minimize risks related to cardiovascular health, cognitive impairment and dementia, and polypharmacy concerns
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Benjamin M. Brucker, MD
Director, Division of Female Pelvic Medicine & Reconstructive Surgery and
Neurourology
Program Director, FPMRS Fellowship
Departments of Urology and Obstetrics & Gynecology
New York University
Langone Health
New York, New York
Benjamin M. Brucker, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Palette Life
Sciences, Inc.; Urovant Sciences Inc.; and Watkins-Conti Products.
Speaker for AbbVie Inc.; Antares Pharma, Inc.; and Urovant
Sciences Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Urovant Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 6/12/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research
StartThis activity expired on July 4, 2024; credit is no longer available.
Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research
Media: Enduring Material
Activity Release Date: June 5, 2023
Activity Expiration Date: July 4, 2024
Time to Complete Activity: 90 minutes
Activity Description
Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical practice.
Target Audience
This activity has been designed to meet the educational needs of oncologists, oncology nurses, advanced practice clinicians, and other healthcare professionals involved in the management of patients with SCLC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the rationale, current or emerging clinical roles, and evidence supporting the use of the latest therapies for SCLC
- Integrate the current standard-of-care therapies into individualized treatment plans of eligible patients with SCLC based on the latest evidence, guideline recommendations, and patient needs/preferences
- Recommend enrollment in clinical trials evaluating current and new/emerging therapies to eligible patients with SCLC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Taofeek K. Owonikoko, MD, PhD
Division Chief, Hematology/Oncology
Stanley M. Marks-OHA Endowed Chair
University of Pittsburgh
Associate Director for Translational Research
Co-Leader, Cancer Therapeutics Program
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Taofeek K. Owonikoko, MD, PhD, has no financial interests/relationships or affiliations in relation to this activity.
Faculty/Planner
Carl M. Gay, MD, PhD
Assistant Professor
Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Carl M. Gay, MD, PhD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb;
Jazz Pharmaceuticals, Inc.; and Monte Rosa Therapeutics.
Grant/Research Support from AstraZeneca.
Speaker for AstraZeneca and BeiGene, Inc.
Faculty/Planner
Ticiana Leal, MD
Associate Professor
Department of Hematology & Oncology
Director, Thoracic Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Ticiana Leal, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Catalyst
Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono;
F-Hoffman LaRoche; G1 Therapeutics, Inc.; Janssen Global Services, LLC; Jazz
Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novocure
GmbH; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company
Limited.
Grant/Research Support from Advaxis Immunotherapies (to the
institution) and Pfizer.
Speakers Bureau participant with Amgen Inc.; AstraZeneca; Catalyst
Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono;
F-Hoffman LaRoche; G1 Therapeutics, Inc.; Janssen Global Services, LLC; Jazz
Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novocure
GmbH; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company
Limited.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca and Jazz Pharmaceuticals, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 7/4/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on July 4, 2024; credit is no longer available.
Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research
Media: Enduring Material
Activity Release Date: June 5, 2023
Activity Expiration Date: July 4, 2024
Time to Complete Activity: 90 minutes
Activity Description
Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical practice.
Target Audience
This activity has been designed to meet the educational needs of oncologists, oncology nurses, advanced practice clinicians, and other healthcare professionals involved in the management of patients with SCLC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the rationale, current or emerging clinical roles, and evidence supporting the use of the latest therapies for SCLC
- Integrate the current standard-of-care therapies into individualized treatment plans of eligible patients with SCLC based on the latest evidence, guideline recommendations, and patient needs/preferences
- Recommend enrollment in clinical trials evaluating current and new/emerging therapies to eligible patients with SCLC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Taofeek K. Owonikoko, MD, PhD
Division Chief, Hematology/Oncology
Stanley M. Marks-OHA Endowed Chair
University of Pittsburgh
Associate Director for Translational Research
Co-Leader, Cancer Therapeutics Program
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Taofeek K. Owonikoko, MD, PhD, has no financial interests/relationships or affiliations in relation to this activity.
Faculty/Planner
Carl M. Gay, MD, PhD
Assistant Professor
Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Carl M. Gay, MD, PhD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb;
Jazz Pharmaceuticals, Inc.; and Monte Rosa Therapeutics.
Grant/Research Support from AstraZeneca.
Speaker for AstraZeneca and BeiGene, Inc.
Faculty/Planner
Ticiana Leal, MD
Associate Professor
Department of Hematology & Oncology
Director, Thoracic Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Ticiana Leal, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Catalyst
Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono;
F-Hoffman LaRoche; G1 Therapeutics, Inc.; Janssen Global Services, LLC; Jazz
Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novocure
GmbH; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company
Limited.
Grant/Research Support from Advaxis Immunotherapies (to the
institution) and Pfizer.
Speakers Bureau participant with Amgen Inc.; AstraZeneca; Catalyst
Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono;
F-Hoffman LaRoche; G1 Therapeutics, Inc.; Janssen Global Services, LLC; Jazz
Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novocure
GmbH; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company
Limited.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca and Jazz Pharmaceuticals, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 7/4/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Immunotherapy for the Win Against Melanoma: Strategies for Integrating Innovative and Next-Generation Immunotherapy Options
StartThis activity expired on July 3, 2024; credit is no longer available.
Immunotherapy for the Win Against Melanoma: Strategies for Integrating Innovative and Next-Generation Immunotherapy Options
Media: Enduring Material
Activity Release Date: June 4, 2023
Activity Expiration Date: July 3, 2024
Time to Complete Activity: 90 minutes
Activity Description
In this activity, based on a recent symposium held during the 2023 ASCO Annual Meeting, leading experts guide you through the winning era of immunotherapy in melanoma. Through a series of linked lectures and debates, the panel discusses the integration of modern immunotherapy combination and sequential options in advanced disease and considers options for patients progressing on prior immunotherapy. They also examine new developments with immunotherapy in the adjuvant and neoadjuvant settings.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, surgical oncologists, dermatologists, advanced practice clinicians, and other clinicians involved in the care of patients with melanoma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss current guidelines, efficacy, and safety data surrounding the use of immunotherapy in melanoma as neoadjuvant or adjuvant therapy in resectable disease or as part of novel combinatorial or sequential approaches for unresectable disease
- Craft team-based treatment plans that include immunotherapy for resectable and unresectable melanoma, including BRAF-mutant or BRAF wild-type disease, based on updated evidence and guideline recommendations
- Develop management strategies for the unique adverse events associated with immunotherapy for patients with melanoma across the spectrum of disease
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Jason J. Luke, MD, FACP
Interim Associate Director for Clinical Research
Director - Immunotherapy and Drug Development Center
Associate Professor of Medicine
UPMC Hillman Cancer Center and University of Pittsburgh
Pittsburgh, Pennsylvania
Jason J. Luke, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for 7 Hills Pharma LLC; AbbVie Inc.; Actym
Therapeutics, Inc.; Affivant Sciences, Inc.; Agenus Inc.; Alnylam
Pharmaceuticals, Inc.; Alphamab Oncology; Arch Oncology; AstraZeneca;
Atomwise Inc.; Bayer HealthCare Pharmaceuticals Inc.; BioCytics; Bright Peak
Therapeutics; Bristol Myers Squibb; Castle Biosciences, Inc.; Checkmate
Pharmaceuticals; Codiak BioSciences; Crown Pharmaceuticals; Cugene Inc.;
Curadev; Day One Biopharmaceuticals, Inc.; Duke Street Bio Ltd; Exo
Therapeutics, Inc.; Eisai Co., Ltd; EMD Serono; Endeavor Biomedicines; F-Star
Therapeutics Inc.; Flame pharmaceuticals; G1 Therapeutics, Inc.; Genentech,
Inc.; Gilead Sciences, Inc.; Glenmark Pharmaceuticals; HotSpot Therapeutics,
Inc.; Ikena Oncology; Immatics US, Inc.; Immunocore Ltd; Incyte; Instil Bio;
Inzen Therapeutics Inc.; IO Biotech; Janssen Pharmaceuticals, Inc.; Kadmon
Corporation; KSQ Therapeutics, Inc.; Kanaph Therapeutics Inc; MacroGenics,
Inc.; Mavu; Merck & Co., Inc.; Mersana Therapeutics Inc.; Nektar; NeoTX;
Novartis Pharmaceuticals Corporation; Onc.AI; OncoNano Medicine; Partners
Pharma; Pfizer; physIQ; Pioneering Medicines; PsiOxus; Pyxis Technologies
Inc.; RefleXion; Regeneron Pharmaceuticals Inc.; Replimune Group Inc.; Ribon
Therapeutics; Roivant Sciences Ltd; Saros Therapeutics; Servier
Pharmaceuticals LLC; Stingthera, Inc.; STipe Therapeutics; Synlogic;
Synthekine; Tempest Therapeutics, Inc.; and Xilio Therapeutics.
Grant/Research Support from AbbVie Inc.; Astellas Pharma Inc.;
AstraZeneca; Bristol Myers Squibb; Corvus Pharmaceuticals; Day One Biopharmaceuticals, Inc.; EMD
Serono; F-Star Therapeutics Inc.; Genmab A/S; HotSpot Therapeutics, Inc.;
Ikena Oncology; Immatics US, Inc.; Incyte; Kadmon Corporation; KAHR;
MacroGenics, Inc.; Merck & Co., Inc.; Moderna, Inc.; Nektar; NextCure, Inc.;
Numab; Palleon Pharmaceuticals; Pfizer; Replimune Group Inc.; Rubius
Therapeutics Inc.; Servier Pharmaceuticals LLC; Scholar Rock; Synlogic;
Takeda Pharmaceutical Company; Trishula Therapeutics, Inc.; Tizona
Therapeutics, Inc.; and Xencor.
Stock Shareholder in Actym Therapeutics, Inc.; Alphamab Oncology;
Arch Oncology; Duke Street Bio Ltd; Kanaph Therapeutics Inc; Mavu; NeoTX;
Onc.AI; OncoNano Medicine; physIQ; Pyxis Technologies Inc.; Saros
Therapeutics; STipe Therapeutics; and Tempest Therapeutics, Inc.
Data Safety Monitoring Board for AbbVie Inc.; Agenus Inc.; Evaxion
Biotech; and Immutep Limited.
Faculty/Planner
Kari Kendra, MD, PhD
Professor
Department of Internal Medicine, Division of Medical Oncology
Director, Cutaneous Oncology Program
Chair, Melanoma Disease Specific Research Committee
The Ohio State University Comprehensive Cancer Center - Arthur G. James
Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio
Kari Kendra, MD, PhD, has a financial interest/relationship or affiliation
in the form of:
Grant/Research Support from Bristol Myers Squibb (institutional
support); Checkmate Pharmaceuticals, Inc.; GlaxoSmithKline; Immunocore Ltd;
Merck & Co., Inc.; Medpace; Novartis Pharmaceuticals Corporation; and Varian
Medical Systems.
Faculty/Planner
Meredith McKean, MD, MPH
Director, Melanoma and Skin Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee
Meredith McKean, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Castle Biosciences, Inc.; Eisai Co.,
Ltd.; IQVIA Inc.; iTeos Therapeutics; Merck & Co., Inc.; Moderna, Inc.; and
Pfizer.
Grant/Research Support from Aadi Bioscience, Inc.; Alpine Immune
Sciences; Arcus Biosciences, Inc.; Arvinas; Ascentage Pharma; ASCO; Astellas
Pharma Inc.; Bayer HealthCare Pharmaceuticals Inc.; Bicycle Therapeutics;
BioMed Valley Discoveries, Inc.; BioNTech SE; C4 Therapeutics, Inc.;
Dragonfly Therapeutics; EMD Serono; Epizyme, Inc.; Erasca, Inc.; Exelixis,
Inc.; Foghorn Therapeutics; G1 Therapeutics, Inc.; Genentech, Inc./F.
Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; GSK; IDEAYA Biosciences; Ikena
Oncology; ImmVira
Pharma; Infinity Pharmaceuticals, Inc.; Jacobio Pharmaceuticals; Kechow
Pharma; Kezar Life Sciences Inc.; Kinnate Biopharma Inc.;
MedImmune; Mereo Biopharma
Group PLC; Metabomed Ltd.; Moderna, Inc.; NBE-Therapeutics AG; Nektar;
Novartis Pharmaceuticals Corporation; OncoC4; Oncorus, Inc.; PACT Pharma,
Inc.; Pfizer; Plexxikon; Poseida Therapeutics, Inc.; Prelude Therapeutics;
Pyramid
Biosciences; Regeneron Pharmaceuticals Inc.; Sapience
Therapeutics, Inc.; Scholar
Rock; Seattle Genetics; Synthrox; Takeda Pharmaceutical
Company; TeneoBio; Tempest Therapeutics, Inc.; Tizona Therapeutics, Inc.;
Tmunity Therapeutics, Inc.; TopAlliance
Biosciences; and Xilio Therapeutics.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from Merck & Co., Inc., and Regeneron Pharmaceuticals, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 7/3/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on July 3, 2024; credit is no longer available.
Immunotherapy for the Win Against Melanoma: Strategies for Integrating Innovative and Next-Generation Immunotherapy Options
Media: Enduring Material
Activity Release Date: June 4, 2023
Activity Expiration Date: July 3, 2024
Time to Complete Activity: 90 minutes
Activity Description
In this activity, based on a recent symposium held during the 2023 ASCO Annual Meeting, leading experts guide you through the winning era of immunotherapy in melanoma. Through a series of linked lectures and debates, the panel discusses the integration of modern immunotherapy combination and sequential options in advanced disease and considers options for patients progressing on prior immunotherapy. They also examine new developments with immunotherapy in the adjuvant and neoadjuvant settings.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, surgical oncologists, dermatologists, advanced practice clinicians, and other clinicians involved in the care of patients with melanoma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss current guidelines, efficacy, and safety data surrounding the use of immunotherapy in melanoma as neoadjuvant or adjuvant therapy in resectable disease or as part of novel combinatorial or sequential approaches for unresectable disease
- Craft team-based treatment plans that include immunotherapy for resectable and unresectable melanoma, including BRAF-mutant or BRAF wild-type disease, based on updated evidence and guideline recommendations
- Develop management strategies for the unique adverse events associated with immunotherapy for patients with melanoma across the spectrum of disease
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Jason J. Luke, MD, FACP
Interim Associate Director for Clinical Research
Director - Immunotherapy and Drug Development Center
Associate Professor of Medicine
UPMC Hillman Cancer Center and University of Pittsburgh
Pittsburgh, Pennsylvania
Jason J. Luke, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for 7 Hills Pharma LLC; AbbVie Inc.; Actym
Therapeutics, Inc.; Affivant Sciences, Inc.; Agenus Inc.; Alnylam
Pharmaceuticals, Inc.; Alphamab Oncology; Arch Oncology; AstraZeneca;
Atomwise Inc.; Bayer HealthCare Pharmaceuticals Inc.; BioCytics; Bright Peak
Therapeutics; Bristol Myers Squibb; Castle Biosciences, Inc.; Checkmate
Pharmaceuticals; Codiak BioSciences; Crown Pharmaceuticals; Cugene Inc.;
Curadev; Day One Biopharmaceuticals, Inc.; Duke Street Bio Ltd; Exo
Therapeutics, Inc.; Eisai Co., Ltd; EMD Serono; Endeavor Biomedicines; F-Star
Therapeutics Inc.; Flame pharmaceuticals; G1 Therapeutics, Inc.; Genentech,
Inc.; Gilead Sciences, Inc.; Glenmark Pharmaceuticals; HotSpot Therapeutics,
Inc.; Ikena Oncology; Immatics US, Inc.; Immunocore Ltd; Incyte; Instil Bio;
Inzen Therapeutics Inc.; IO Biotech; Janssen Pharmaceuticals, Inc.; Kadmon
Corporation; KSQ Therapeutics, Inc.; Kanaph Therapeutics Inc; MacroGenics,
Inc.; Mavu; Merck & Co., Inc.; Mersana Therapeutics Inc.; Nektar; NeoTX;
Novartis Pharmaceuticals Corporation; Onc.AI; OncoNano Medicine; Partners
Pharma; Pfizer; physIQ; Pioneering Medicines; PsiOxus; Pyxis Technologies
Inc.; RefleXion; Regeneron Pharmaceuticals Inc.; Replimune Group Inc.; Ribon
Therapeutics; Roivant Sciences Ltd; Saros Therapeutics; Servier
Pharmaceuticals LLC; Stingthera, Inc.; STipe Therapeutics; Synlogic;
Synthekine; Tempest Therapeutics, Inc.; and Xilio Therapeutics.
Grant/Research Support from AbbVie Inc.; Astellas Pharma Inc.;
AstraZeneca; Bristol Myers Squibb; Corvus Pharmaceuticals; Day One Biopharmaceuticals, Inc.; EMD
Serono; F-Star Therapeutics Inc.; Genmab A/S; HotSpot Therapeutics, Inc.;
Ikena Oncology; Immatics US, Inc.; Incyte; Kadmon Corporation; KAHR;
MacroGenics, Inc.; Merck & Co., Inc.; Moderna, Inc.; Nektar; NextCure, Inc.;
Numab; Palleon Pharmaceuticals; Pfizer; Replimune Group Inc.; Rubius
Therapeutics Inc.; Servier Pharmaceuticals LLC; Scholar Rock; Synlogic;
Takeda Pharmaceutical Company; Trishula Therapeutics, Inc.; Tizona
Therapeutics, Inc.; and Xencor.
Stock Shareholder in Actym Therapeutics, Inc.; Alphamab Oncology;
Arch Oncology; Duke Street Bio Ltd; Kanaph Therapeutics Inc; Mavu; NeoTX;
Onc.AI; OncoNano Medicine; physIQ; Pyxis Technologies Inc.; Saros
Therapeutics; STipe Therapeutics; and Tempest Therapeutics, Inc.
Data Safety Monitoring Board for AbbVie Inc.; Agenus Inc.; Evaxion
Biotech; and Immutep Limited.
Faculty/Planner
Kari Kendra, MD, PhD
Professor
Department of Internal Medicine, Division of Medical Oncology
Director, Cutaneous Oncology Program
Chair, Melanoma Disease Specific Research Committee
The Ohio State University Comprehensive Cancer Center - Arthur G. James
Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio
Kari Kendra, MD, PhD, has a financial interest/relationship or affiliation
in the form of:
Grant/Research Support from Bristol Myers Squibb (institutional
support); Checkmate Pharmaceuticals, Inc.; GlaxoSmithKline; Immunocore Ltd;
Merck & Co., Inc.; Medpace; Novartis Pharmaceuticals Corporation; and Varian
Medical Systems.
Faculty/Planner
Meredith McKean, MD, MPH
Director, Melanoma and Skin Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee
Meredith McKean, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Castle Biosciences, Inc.; Eisai Co.,
Ltd.; IQVIA Inc.; iTeos Therapeutics; Merck & Co., Inc.; Moderna, Inc.; and
Pfizer.
Grant/Research Support from Aadi Bioscience, Inc.; Alpine Immune
Sciences; Arcus Biosciences, Inc.; Arvinas; Ascentage Pharma; ASCO; Astellas
Pharma Inc.; Bayer HealthCare Pharmaceuticals Inc.; Bicycle Therapeutics;
BioMed Valley Discoveries, Inc.; BioNTech SE; C4 Therapeutics, Inc.;
Dragonfly Therapeutics; EMD Serono; Epizyme, Inc.; Erasca, Inc.; Exelixis,
Inc.; Foghorn Therapeutics; G1 Therapeutics, Inc.; Genentech, Inc./F.
Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; GSK; IDEAYA Biosciences; Ikena
Oncology; ImmVira
Pharma; Infinity Pharmaceuticals, Inc.; Jacobio Pharmaceuticals; Kechow
Pharma; Kezar Life Sciences Inc.; Kinnate Biopharma Inc.;
MedImmune; Mereo Biopharma
Group PLC; Metabomed Ltd.; Moderna, Inc.; NBE-Therapeutics AG; Nektar;
Novartis Pharmaceuticals Corporation; OncoC4; Oncorus, Inc.; PACT Pharma,
Inc.; Pfizer; Plexxikon; Poseida Therapeutics, Inc.; Prelude Therapeutics;
Pyramid
Biosciences; Regeneron Pharmaceuticals Inc.; Sapience
Therapeutics, Inc.; Scholar
Rock; Seattle Genetics; Synthrox; Takeda Pharmaceutical
Company; TeneoBio; Tempest Therapeutics, Inc.; Tizona Therapeutics, Inc.;
Tmunity Therapeutics, Inc.; TopAlliance
Biosciences; and Xilio Therapeutics.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from Merck & Co., Inc., and Regeneron Pharmaceuticals, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 7/3/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now
StartThis activity expired on July 2, 2024; credit is no longer available.
New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now
Activity Description and Educational Objectives
Recent research and improved understanding of the pathogenesis of multiple
sclerosis (MS) has led to the development of multiple biomarkers and imaging
modalities that can improve clinicians’ ability to individualize therapy
through more effective monitoring of disease progression and treatment
response. The promise of eventually arriving at data-driven personalized
care—coupled with the number of available and emerging therapies for MS
treatment—makes it more important than ever that clinicians remain up-to-date
on advances in biomarkers and imaging approaches, as well as shared
decision-making strategies.
In this activity, based on a recent live symposium, MS experts cover the
latest data on these new and emerging biomarkers for MS management. Using
examples from their own practice, the panelists also discuss ways to
incorporate these biomarker findings into individualized treatment decisions
to empower patients and improve treatment outcomes.
Upon completion of this activity, participants should be better able to:
- Describe emerging biomarkers that may play a role in evaluating MS disease activity, progression, and treatment response
- Individualize treatment decisions for patients with MS, incorporating biomarker findings, disease status, and other patient-specific characteristics
- Integrate team-based shared decision-making strategies to facilitate appropriate treatment selection, empower patients, and improve outcomes
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. There are no prerequisites and
there is no fee to participate in this activity or to receive
CME/NCPD/CPE/IPCE credit. Statements of Credit are awarded upon successful
completion of the post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Media: Enduring Material
Release and Expiration Dates: June 3, 2023 - July 2, 2024
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.
Chair & Moderator
Jiwon Oh, MD, PhD, FRCPC
Medical Director, Barlo Multiple Sclerosis Program
Associate Professor, Division of Neurology
St. Michael’s Hospital
University of Toronto
Staff Neurologist
Scientist
Keenan Research Centre of the Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada
Jiwon Oh, MD, PhD, FRCPC, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; Bristol Myers
Squibb; EMD Serono Canada; F. Hoffmann-La Roche Ltd; Lilly; Novartis
Pharmaceuticals Canada Inc.; and Sanofi/Genzyme Canada Inc.
Grant/Research Support from Biogen Canada Inc.; EMD Serono Canada;
and F. Hoffmann-La Roche Ltd.
Speaker for Biogen Canada Inc.; Bristol Myers Squibb; EMD Serono
Canada; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Canada Inc.; and
Sanofi/Genzyme Canada Inc.
Presenters
Jacci Bainbridge, PharmD, FCCP, MSCS, FAES
Professor
Departments of Clinical Pharmacy and Neurology
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado, Anschutz Medical Campus
Aurora, Colorado
Jacci Bainbridge, PharmD, FCCP, MSCS, FAES, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Novartis Pharmaceuticals
Corporation.
Kathleen M. Costello, RN, MS, NP, MSCN
Chief Operating Officer
Can Do-Multiple Sclerosis
Avon, Colorado
Kathleen M. Costello, RN, MS, NP, MSCN, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; Genentech, Inc.; Janssen
Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.
Other PVI staff who may potentially review content for this activity have
disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development
and review of this activity have disclosed no relevant financial
relationships.
All of the relevant financial relationships listed for these individuals have
been mitigated.
Accreditation, Credit, and Support


Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The Penn State College of Medicine designates this enduring material for a
maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Information about CME credit for this activity is available by contacting
Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference
course # G6939-23-T.
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-039-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, and Penn State College of
Medicine are responsible for the selection of this activity’s topics, the
preparation of editorial content, and the distribution of this activity. Our
activities may contain references to unapproved products or uses of these
products in certain jurisdictions. The preparation of PeerView activities is
supported by educational grants subject to written agreements that clearly
stipulate and enforce the editorial independence of PVI and Penn State
College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on July 2, 2024; credit is no longer available.
New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now
Activity Description and Educational Objectives
Recent research and improved understanding of the pathogenesis of multiple
sclerosis (MS) has led to the development of multiple biomarkers and imaging
modalities that can improve clinicians’ ability to individualize therapy
through more effective monitoring of disease progression and treatment
response. The promise of eventually arriving at data-driven personalized
care—coupled with the number of available and emerging therapies for MS
treatment—makes it more important than ever that clinicians remain up-to-date
on advances in biomarkers and imaging approaches, as well as shared
decision-making strategies.
In this activity, based on a recent live symposium, MS experts cover the
latest data on these new and emerging biomarkers for MS management. Using
examples from their own practice, the panelists also discuss ways to
incorporate these biomarker findings into individualized treatment decisions
to empower patients and improve treatment outcomes.
Upon completion of this activity, participants should be better able to:
- Describe emerging biomarkers that may play a role in evaluating MS disease activity, progression, and treatment response
- Individualize treatment decisions for patients with MS, incorporating biomarker findings, disease status, and other patient-specific characteristics
- Integrate team-based shared decision-making strategies to facilitate appropriate treatment selection, empower patients, and improve outcomes
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. There are no prerequisites and
there is no fee to participate in this activity or to receive
CME/NCPD/CPE/IPCE credit. Statements of Credit are awarded upon successful
completion of the post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Media: Enduring Material
Release and Expiration Dates: June 3, 2023 - July 2, 2024
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.
Chair & Moderator
Jiwon Oh, MD, PhD, FRCPC
Medical Director, Barlo Multiple Sclerosis Program
Associate Professor, Division of Neurology
St. Michael’s Hospital
University of Toronto
Staff Neurologist
Scientist
Keenan Research Centre of the Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada
Jiwon Oh, MD, PhD, FRCPC, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; Bristol Myers
Squibb; EMD Serono Canada; F. Hoffmann-La Roche Ltd; Lilly; Novartis
Pharmaceuticals Canada Inc.; and Sanofi/Genzyme Canada Inc.
Grant/Research Support from Biogen Canada Inc.; EMD Serono Canada;
and F. Hoffmann-La Roche Ltd.
Speaker for Biogen Canada Inc.; Bristol Myers Squibb; EMD Serono
Canada; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Canada Inc.; and
Sanofi/Genzyme Canada Inc.
Presenters
Jacci Bainbridge, PharmD, FCCP, MSCS, FAES
Professor
Departments of Clinical Pharmacy and Neurology
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado, Anschutz Medical Campus
Aurora, Colorado
Jacci Bainbridge, PharmD, FCCP, MSCS, FAES, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Novartis Pharmaceuticals
Corporation.
Kathleen M. Costello, RN, MS, NP, MSCN
Chief Operating Officer
Can Do-Multiple Sclerosis
Avon, Colorado
Kathleen M. Costello, RN, MS, NP, MSCN, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; Genentech, Inc.; Janssen
Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.
Other PVI staff who may potentially review content for this activity have
disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development
and review of this activity have disclosed no relevant financial
relationships.
All of the relevant financial relationships listed for these individuals have
been mitigated.
Accreditation, Credit, and Support


Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The Penn State College of Medicine designates this enduring material for a
maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Information about CME credit for this activity is available by contacting
Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference
course # G6939-23-T.
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-039-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, and Penn State College of
Medicine are responsible for the selection of this activity’s topics, the
preparation of editorial content, and the distribution of this activity. Our
activities may contain references to unapproved products or uses of these
products in certain jurisdictions. The preparation of PeerView activities is
supported by educational grants subject to written agreements that clearly
stipulate and enforce the editorial independence of PVI and Penn State
College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the Disease Spectrum
StartThis activity expired on July 2, 2024; credit is no longer available.
Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the Disease Spectrum
Media: Enduring Material
Activity Release Date: June 3, 2023
Activity Expiration Date: July 2, 2024
Time to Complete Activity: 90 minutes
Activity Description
Innovation in renal cell carcinoma (RCC) has brought new opportunities to improve patient outcomes through personalized medicine. With multiple FDA approvals and promising agents being explored in a variety of settings, multitargeted TKIs and immune checkpoint inhibitors have earned their place in cancer care plans either as guideline-recommended therapy or through clinical trial enrollment. In this activity, which was based on a recent live event, a panel of expert oncologists combines a concise overview of essential research on approved and emerging RCC treatments with discussion of real-life patient cases to provide guidance on integrating validated strategies into everyday patient care. Learn how patient-, disease-, and treatment-specific factors affect therapeutic selection and sequencing—including when to consider adjuvant therapy, which patients may benefit from immunotherapy-based combination regimens in the frontline setting, and how to determine which strategies to recommend for patients with relapsed disease. Hear guidance on collaborative approaches to managing adverse events, insights on the use of emerging agents, and updates on clinical trials underway.
Target Audience
This activity has been designed to meet the educational needs of urologic and medical oncologists, urologists, advanced practice clinicians, and other healthcare professionals involved in the management of patients with RCC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Evaluate treatment efficacy and safety of approved and emerging therapeutic regimens for patients with RCC
- Select personalized therapeutic strategies based on current evidence and patient-, disease-, and treatment-specific factors for patients with RCC
- Integrate strategies to anticipate, mitigate, and manage various adverse events associated with treatments for patients with RCC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Sumanta Kumar Pal, MD, FASCO
Professor, Department of Medical Oncology & Therapeutics Research
Co-Director, Kidney Cancer Program
City of Hope Comprehensive Cancer Center
Duarte, California
Sumanta Kumar Pal, MD, FASCO, has a financial interest/relationship or
affiliation in the form of:
Other Financial or Material Support for travel from Crispr
Therapeutics and Ipsen.
Faculty/Planner
Pedro C. Barata, MD, MSc
Director of GU Medical Oncology Research Program
University Hospitals Seidman Cancer Center
Associate Professor of Medicine
Case Western Reserve University
Case Comprehensive Cancer Center
Cleveland, Ohio
Pedro C. Barata, MD, MSc, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; AVEO
Pharmaceuticals, Inc; Bristol Myers Squibb; Clovis Oncology; EMD Serono;
Eisai Co., Ltd.; Exelixis, Inc.; Pfizer; and Sanofi.
Grant/Research Support from Blue Earth Diagnostics and Exelixis,
Inc.
Speakers Bureau participant with Bayer HealthCare Pharmaceuticals,
Inc.; Caris Life Sciences; and Myovant Sciences Ltd.
Faculty/Planner
Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Medical Director, International Strategic Initiatives
Dana-Farber Cancer Institute
The Jerome and Nancy Kohlberg Endowed Chair
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Toni K. Choueiri, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Alkermes; Aravive; AstraZeneca; AVEO
Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers
Squibb; Calithera Biosciences, Inc.; Circle Pharma; Eisai Co., Ltd; EMD
Serono Inc.; Exelixis Inc.; F. Hoffman-La Roche Ltd.; Gilead; GSK; IQVIA;
Infinity Pharmaceuticals, Inc.; Ipsen Pharma; Janssen Pharmaceuticals; Kanaph
Therapeutics Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals
Corporation; Pfizer; Sanofi; Surface Oncology; Takeda Pharmaceutical Company
Limited; and Tempest Therapeutics, Inc.
Stock Shareholder in NiKang Therapeutics, Inc.; Osel Inc.; and
Tempest Therapeutics, Inc.
Other Financial or Material Support Institutional patents filed on
molecular alterations and immunotherapy response/toxicity, and ctDNA. Equity:
Tempest, Pionyr, Osel, Precede Bio, CureResponse. Committees: NCCN, GU
Steering Committee, ASCO/ESMO, ACCRU, KidneyCan. The institution (Dana-Farber
Cancer Institute) may have received additional independent funding of drug
companies or/and royalties potentially involved in research around the
subject matter. T. K. Choueiri is supported in part by the
Dana-Farber/Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program
5P30CA006516-56, the Kohlberg Chair at Harvard Medical School and the Trust
Family, Michael Brigham, Pan Mass Challenge, Hinda and Arthur Marcus Fund and
Loker Pinard Funds for Kidney.
Faculty/Planner
Cristina Suarez, MD, PhD
Senior Researcher
VHIO's Genitourinary, Central Nervous System (CNS) Tumors, Sarcoma and Cancer
of Unknown Primary Site Group
Vall d’Hebron University Hospital
Barcelona, Spain
Cristina Suarez, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; Bayer AG;
Bristol Myers Squibb; F. Hoffman-La Roche Ltd.; Ipsen; Merck Sharp & Dohme;
Pfizer; and Sanofi.
Grant/Research Support from Pfizer.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Kidney Cancer Research Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported by medical education grants from AVEO Pharmaceuticals, Inc., Eisai Inc., Exelixis, Inc., and Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
[Statement:Royal_College_Reciprocity]
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 7/2/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on July 2, 2024; credit is no longer available.
Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the Disease Spectrum
Media: Enduring Material
Activity Release Date: June 3, 2023
Activity Expiration Date: July 2, 2024
Time to Complete Activity: 90 minutes
Activity Description
Innovation in renal cell carcinoma (RCC) has brought new opportunities to improve patient outcomes through personalized medicine. With multiple FDA approvals and promising agents being explored in a variety of settings, multitargeted TKIs and immune checkpoint inhibitors have earned their place in cancer care plans either as guideline-recommended therapy or through clinical trial enrollment. In this activity, which was based on a recent live event, a panel of expert oncologists combines a concise overview of essential research on approved and emerging RCC treatments with discussion of real-life patient cases to provide guidance on integrating validated strategies into everyday patient care. Learn how patient-, disease-, and treatment-specific factors affect therapeutic selection and sequencing—including when to consider adjuvant therapy, which patients may benefit from immunotherapy-based combination regimens in the frontline setting, and how to determine which strategies to recommend for patients with relapsed disease. Hear guidance on collaborative approaches to managing adverse events, insights on the use of emerging agents, and updates on clinical trials underway.
Target Audience
This activity has been designed to meet the educational needs of urologic and medical oncologists, urologists, advanced practice clinicians, and other healthcare professionals involved in the management of patients with RCC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Evaluate treatment efficacy and safety of approved and emerging therapeutic regimens for patients with RCC
- Select personalized therapeutic strategies based on current evidence and patient-, disease-, and treatment-specific factors for patients with RCC
- Integrate strategies to anticipate, mitigate, and manage various adverse events associated with treatments for patients with RCC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Sumanta Kumar Pal, MD, FASCO
Professor, Department of Medical Oncology & Therapeutics Research
Co-Director, Kidney Cancer Program
City of Hope Comprehensive Cancer Center
Duarte, California
Sumanta Kumar Pal, MD, FASCO, has a financial interest/relationship or
affiliation in the form of:
Other Financial or Material Support for travel from Crispr
Therapeutics and Ipsen.
Faculty/Planner
Pedro C. Barata, MD, MSc
Director of GU Medical Oncology Research Program
University Hospitals Seidman Cancer Center
Associate Professor of Medicine
Case Western Reserve University
Case Comprehensive Cancer Center
Cleveland, Ohio
Pedro C. Barata, MD, MSc, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; AVEO
Pharmaceuticals, Inc; Bristol Myers Squibb; Clovis Oncology; EMD Serono;
Eisai Co., Ltd.; Exelixis, Inc.; Pfizer; and Sanofi.
Grant/Research Support from Blue Earth Diagnostics and Exelixis,
Inc.
Speakers Bureau participant with Bayer HealthCare Pharmaceuticals,
Inc.; Caris Life Sciences; and Myovant Sciences Ltd.
Faculty/Planner
Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Medical Director, International Strategic Initiatives
Dana-Farber Cancer Institute
The Jerome and Nancy Kohlberg Endowed Chair
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Toni K. Choueiri, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Alkermes; Aravive; AstraZeneca; AVEO
Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers
Squibb; Calithera Biosciences, Inc.; Circle Pharma; Eisai Co., Ltd; EMD
Serono Inc.; Exelixis Inc.; F. Hoffman-La Roche Ltd.; Gilead; GSK; IQVIA;
Infinity Pharmaceuticals, Inc.; Ipsen Pharma; Janssen Pharmaceuticals; Kanaph
Therapeutics Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals
Corporation; Pfizer; Sanofi; Surface Oncology; Takeda Pharmaceutical Company
Limited; and Tempest Therapeutics, Inc.
Stock Shareholder in NiKang Therapeutics, Inc.; Osel Inc.; and
Tempest Therapeutics, Inc.
Other Financial or Material Support Institutional patents filed on
molecular alterations and immunotherapy response/toxicity, and ctDNA. Equity:
Tempest, Pionyr, Osel, Precede Bio, CureResponse. Committees: NCCN, GU
Steering Committee, ASCO/ESMO, ACCRU, KidneyCan. The institution (Dana-Farber
Cancer Institute) may have received additional independent funding of drug
companies or/and royalties potentially involved in research around the
subject matter. T. K. Choueiri is supported in part by the
Dana-Farber/Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program
5P30CA006516-56, the Kohlberg Chair at Harvard Medical School and the Trust
Family, Michael Brigham, Pan Mass Challenge, Hinda and Arthur Marcus Fund and
Loker Pinard Funds for Kidney.
Faculty/Planner
Cristina Suarez, MD, PhD
Senior Researcher
VHIO's Genitourinary, Central Nervous System (CNS) Tumors, Sarcoma and Cancer
of Unknown Primary Site Group
Vall d’Hebron University Hospital
Barcelona, Spain
Cristina Suarez, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; Bayer AG;
Bristol Myers Squibb; F. Hoffman-La Roche Ltd.; Ipsen; Merck Sharp & Dohme;
Pfizer; and Sanofi.
Grant/Research Support from Pfizer.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Kidney Cancer Research Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported by medical education grants from AVEO Pharmaceuticals, Inc., Eisai Inc., Exelixis, Inc., and Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
[Statement:Royal_College_Reciprocity]
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 7/2/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Defying the Odds With Innovation in CLL: Perspectives on Personalized Care, Multiagent Platforms, and Sequential Strategies
StartThis activity expired on July 2, 2024; credit is no longer available.
Defying the Odds With Innovation in CLL: Perspectives on Personalized Care, Multiagent Platforms, and Sequential Strategies
Media: Enduring Material
Activity Release Date: June 3, 2023
Activity Expiration Date: July 2, 2024
Time to Complete Activity: 90 minutes
Activity Description
Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decisions.
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, physician assistants, nurse practitioners, and other clinicians involved in the management of patients with chronic lymphocytic leukemia.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize safety/efficacy evidence and practice guidelines that support the use of novel targeted and emerging immunotherapy agents in CLL, such as BTK and BCL2 inhibitors, CAR-T cells, and bispecifics
- Integrate novel and emerging targeted strategies into personalized single-agent and combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations
- Develop appropriate sequential treatment plans with targeted agents and emerging immunotherapy options for patients with therapeutic intolerance and/or R/R CLL
- Implement evidence-based protocols to address the unique safety considerations associated with the use of targeted agents and emerging immunotherapy options in the CLL setting
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Matthew S. Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Co-Leader for Lymphoma of Dana-Farber/Harvard Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Matthew S. Davids, MD, MMSc, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies;
Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb;
Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co.,
Inc.; Mingsight Pharmaceuticals Inc.; Ono Pharmaceutical Co., Ltd.; Secura
Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.
Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca;
Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG
Therapeutics, Inc.
Honoraria from Aptitude Health; Bio Ascend; and Curio Science.
Other Financial or Material Support in the form of Royalties from
Up-to-Date.
Faculty/Planner
Adam Scott Kittai, MD
Assistant Professor – Clinical, Division of Hematology
Department of Internal Medicine
The Ohio State University
Columbus, Ohio
Adam Scott Kittai, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene, Inc.;
Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company;
and Lilly.
Grant/Research Support from AstraZeneca.
Speaker for AbbVie; BeiGene, Inc.; and Bristol Myers
Squibb.
Faculty/Planner
Nicole Lamanna, MD
Associate Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Columbia University Irving Medical Center
Herbert Irving Comprehensive Cancer Center
New York, New York
Nicole Lamanna, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies;
AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.;
and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.;
Genentech, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.;
Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics,
Inc.
Faculty/Planner
William G. Wierda, MD, PhD
Professor, Department of Leukemia, Division of Cancer Medicine
D.B. Lane Cancer Research Distinguished Professor
Section Chief - Chronic Lymphocytic Leukemia
Center Medical Director
Executive Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas
William G. Wierda, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Grant/Research Support from AbbVie; Acerta Pharma; Bristol Myers
Squibb; Cyclacel Pharmaceuticals Inc.; Genentech, Inc.; Gilead Sciences,
Inc.; GlaxoSmithKline; Janssen Biotech, Inc.; Juno Pharmaceuticals; Kite, A
Gilead Company; Loxo Oncology, Inc.; miRagen Therapeutics, Inc.; Novartis
Pharmaceuticals Corporation; Oncternal Therapeutics; Pharmacyclics, Inc.;
Sunesis Pharmaceuticals, Inc.; and Xencor.
Other Financial or Material Support Nonrelevant Financial
Relationship: National Comprehensive Cancer Network (Chair & CLL).
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AbbVie, AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 7/2/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on July 2, 2024; credit is no longer available.
Defying the Odds With Innovation in CLL: Perspectives on Personalized Care, Multiagent Platforms, and Sequential Strategies
Media: Enduring Material
Activity Release Date: June 3, 2023
Activity Expiration Date: July 2, 2024
Time to Complete Activity: 90 minutes
Activity Description
Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decisions.
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, physician assistants, nurse practitioners, and other clinicians involved in the management of patients with chronic lymphocytic leukemia.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize safety/efficacy evidence and practice guidelines that support the use of novel targeted and emerging immunotherapy agents in CLL, such as BTK and BCL2 inhibitors, CAR-T cells, and bispecifics
- Integrate novel and emerging targeted strategies into personalized single-agent and combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations
- Develop appropriate sequential treatment plans with targeted agents and emerging immunotherapy options for patients with therapeutic intolerance and/or R/R CLL
- Implement evidence-based protocols to address the unique safety considerations associated with the use of targeted agents and emerging immunotherapy options in the CLL setting
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Matthew S. Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Co-Leader for Lymphoma of Dana-Farber/Harvard Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Matthew S. Davids, MD, MMSc, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies;
Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb;
Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co.,
Inc.; Mingsight Pharmaceuticals Inc.; Ono Pharmaceutical Co., Ltd.; Secura
Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.
Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca;
Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG
Therapeutics, Inc.
Honoraria from Aptitude Health; Bio Ascend; and Curio Science.
Other Financial or Material Support in the form of Royalties from
Up-to-Date.
Faculty/Planner
Adam Scott Kittai, MD
Assistant Professor – Clinical, Division of Hematology
Department of Internal Medicine
The Ohio State University
Columbus, Ohio
Adam Scott Kittai, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene, Inc.;
Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company;
and Lilly.
Grant/Research Support from AstraZeneca.
Speaker for AbbVie; BeiGene, Inc.; and Bristol Myers
Squibb.
Faculty/Planner
Nicole Lamanna, MD
Associate Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Columbia University Irving Medical Center
Herbert Irving Comprehensive Cancer Center
New York, New York
Nicole Lamanna, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies;
AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.;
and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.;
Genentech, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.;
Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics,
Inc.
Faculty/Planner
William G. Wierda, MD, PhD
Professor, Department of Leukemia, Division of Cancer Medicine
D.B. Lane Cancer Research Distinguished Professor
Section Chief - Chronic Lymphocytic Leukemia
Center Medical Director
Executive Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas
William G. Wierda, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Grant/Research Support from AbbVie; Acerta Pharma; Bristol Myers
Squibb; Cyclacel Pharmaceuticals Inc.; Genentech, Inc.; Gilead Sciences,
Inc.; GlaxoSmithKline; Janssen Biotech, Inc.; Juno Pharmaceuticals; Kite, A
Gilead Company; Loxo Oncology, Inc.; miRagen Therapeutics, Inc.; Novartis
Pharmaceuticals Corporation; Oncternal Therapeutics; Pharmacyclics, Inc.;
Sunesis Pharmaceuticals, Inc.; and Xencor.
Other Financial or Material Support Nonrelevant Financial
Relationship: National Comprehensive Cancer Network (Chair & CLL).
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AbbVie, AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 7/2/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Renovating the Clinical Rulebook for HCC: Multidirectional Management With Innovative Immunotherapy and Targeted Platforms
StartThis activity expired on July 2, 2024; credit is no longer available.
Renovating the Clinical Rulebook for HCC: Multidirectional Management With Innovative Immunotherapy and Targeted Platforms
Media: Enduring Material
Activity Release Date: June 3, 2023
Activity Expiration Date: July 2, 2024
Time to Complete Activity: 90 minutes
Activity Description
Approaches to managing patients with hepatocellular carcinoma (HCC) are
undergoing renovation! A recent wave of improved therapeutic regimens,
including immunotherapy/anti-VEGF combinations (eg, atezolizumab and
bevacizumab), dual immunotherapy combinations (ie, durvalumab-tremelimumab),
and next-generation TKIs (ie, lenvatinib) has been introduced in the upfront
setting. Recent additions to the second-line setting have delivered improved
options for patients with HCC including immune checkpoint inhibitors (eg,
pembrolizumab and tislelizumab) and multikinase inhibitors (ie, cabozantinib
and regorafenib). Emerging data on other up-and-coming targeted platforms are
forthcoming, including evidence for perioperative applications in earlier
disease settings. With all of these developments, how should we update our
clinical rulebooks for treating HCC?
This activity, based on a recent live symposium, uncovers innovative
treatment strategies in early and intermediate HCC and presents validated and
emerging strategies in advanced HCC. The unique Tumor Board format uses
case-based scenarios to facilitate an interactive discussion covering
practical guidance you can use to renovate your own clinical rulebook.
Target Audience
This activity has been designed to meet the educational needs of gastrointestinal oncologists, medical oncologists, interventional radiologists, hepatologists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with HCC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Examine the latest clinical evidence supporting the use of immunotherapy, targeted therapy, and combination regimens for the management of HCC
- Integrate individualized treatment plans for patients with HCC based on the latest clinical evidence, expert recommendations, and patient-specific factors
- Employ team-based strategies and practical considerations when integrating novel HCC regimens, including monitoring, patient consultation, and adverse event management
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Ghassan Abou-Alfa, MD, MBA
Professor
Memorial Sloan Kettering Cancer Center
New York, New York
Ghassan Abou-Alfa, MD, MBA, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; AstraZeneca;
Autem Therapeutics; Berry Genomics; BioNTech; Boehringer Ingelheim
Pharmaceuticals, Inc.; Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; FibroGen, Inc.; Helios Pharmaceutical;
Incyte; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; NewBridge
Pharmaceuticals; Novartis Pharmaceuticals Corporation; QED Therapeutics;
Servier Laboratories; and Tempus.
Grant/Research Support from Agenus Inc.; Arcus Biosciences, Inc.;
AstraZeneca; BioNTech; Bristol Myers Squibb; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Helsinn Healthcare SA; Parker Institute for Cancer
Immunotherapy; Pertzye; Puma Biotechnology, Inc.; QED Therapeutics; and
Yiviva.
Faculty/Planner
Lipika Goyal, MD
Associate Professor of Medicine
Division of Oncology
Stanford School of Medicine
Stanford, California
Lipika Goyal, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Alentis Therapeutics AG; Basilea
Pharmaceutica; Black Diamond Therapeutics, Inc.; Blueprint Medicines
Corporation; Eisai Inc./H3Biomedicine; Exelixis, Inc.; Genentech, Inc.; H3
Biomedicine; Incyte Corporation; Kinnate Biopharma Inc.; Merck & Co., Inc.;
QED Therapeutics; Relay Therapeutics; Servier Pharmaceuticals; Sirtex Medical
Ltd; Surface Oncology; Taiho Oncology, Inc.; and TransThera
Biosciences.
Data Safety Monitoring Board for AstraZeneca.
Faculty/Planner
Ahmed Omar Kaseb, MD, CMQ
Endowed Professor and Director, Hepatocellular Carcinoma Program
Member, NCI Hepatobiliary Task Force
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Ahmed Omar Kaseb, MD, CMQ, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Adaptimmune Therapeutics and Polaris
Pharmaceuticals Inc.
Grant/Research Support from Adaptimmune Therapeutics; AstraZeneca;
Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Merck & Co., Inc.; and Polaris Pharmaceuticals
Inc.
Faculty/Planner
Amit Singal, MD, MS
Professor of Medicine
Willis C. Maddrey Chair in Liver Disease
Chief of Hepatology and Medical Director of the Liver Tumor Program
UT Southwestern Medical Center
Dallas, Texas
Amit Singal, MD, MS, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Boston
Scientific; Eisai Inc.; Exact Sciences Corporation; Exelixis, Inc.; FujiFilm
Medical; Genentech, Inc.; Glycotest, Inc.; GRAIL, Inc; and Universal
Diagnostics.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Blue Faery: The Adrienne Wilson Liver Cancer Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported by independent medical education grants from AstraZeneca, Eisai Inc., Exelixis, Inc., Merck & Co., Inc., and Novocure, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 7/2/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on July 2, 2024; credit is no longer available.
Renovating the Clinical Rulebook for HCC: Multidirectional Management With Innovative Immunotherapy and Targeted Platforms
Media: Enduring Material
Activity Release Date: June 3, 2023
Activity Expiration Date: July 2, 2024
Time to Complete Activity: 90 minutes
Activity Description
Approaches to managing patients with hepatocellular carcinoma (HCC) are
undergoing renovation! A recent wave of improved therapeutic regimens,
including immunotherapy/anti-VEGF combinations (eg, atezolizumab and
bevacizumab), dual immunotherapy combinations (ie, durvalumab-tremelimumab),
and next-generation TKIs (ie, lenvatinib) has been introduced in the upfront
setting. Recent additions to the second-line setting have delivered improved
options for patients with HCC including immune checkpoint inhibitors (eg,
pembrolizumab and tislelizumab) and multikinase inhibitors (ie, cabozantinib
and regorafenib). Emerging data on other up-and-coming targeted platforms are
forthcoming, including evidence for perioperative applications in earlier
disease settings. With all of these developments, how should we update our
clinical rulebooks for treating HCC?
This activity, based on a recent live symposium, uncovers innovative
treatment strategies in early and intermediate HCC and presents validated and
emerging strategies in advanced HCC. The unique Tumor Board format uses
case-based scenarios to facilitate an interactive discussion covering
practical guidance you can use to renovate your own clinical rulebook.
Target Audience
This activity has been designed to meet the educational needs of gastrointestinal oncologists, medical oncologists, interventional radiologists, hepatologists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with HCC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Examine the latest clinical evidence supporting the use of immunotherapy, targeted therapy, and combination regimens for the management of HCC
- Integrate individualized treatment plans for patients with HCC based on the latest clinical evidence, expert recommendations, and patient-specific factors
- Employ team-based strategies and practical considerations when integrating novel HCC regimens, including monitoring, patient consultation, and adverse event management
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Ghassan Abou-Alfa, MD, MBA
Professor
Memorial Sloan Kettering Cancer Center
New York, New York
Ghassan Abou-Alfa, MD, MBA, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; AstraZeneca;
Autem Therapeutics; Berry Genomics; BioNTech; Boehringer Ingelheim
Pharmaceuticals, Inc.; Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; FibroGen, Inc.; Helios Pharmaceutical;
Incyte; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; NewBridge
Pharmaceuticals; Novartis Pharmaceuticals Corporation; QED Therapeutics;
Servier Laboratories; and Tempus.
Grant/Research Support from Agenus Inc.; Arcus Biosciences, Inc.;
AstraZeneca; BioNTech; Bristol Myers Squibb; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Helsinn Healthcare SA; Parker Institute for Cancer
Immunotherapy; Pertzye; Puma Biotechnology, Inc.; QED Therapeutics; and
Yiviva.
Faculty/Planner
Lipika Goyal, MD
Associate Professor of Medicine
Division of Oncology
Stanford School of Medicine
Stanford, California
Lipika Goyal, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Alentis Therapeutics AG; Basilea
Pharmaceutica; Black Diamond Therapeutics, Inc.; Blueprint Medicines
Corporation; Eisai Inc./H3Biomedicine; Exelixis, Inc.; Genentech, Inc.; H3
Biomedicine; Incyte Corporation; Kinnate Biopharma Inc.; Merck & Co., Inc.;
QED Therapeutics; Relay Therapeutics; Servier Pharmaceuticals; Sirtex Medical
Ltd; Surface Oncology; Taiho Oncology, Inc.; and TransThera
Biosciences.
Data Safety Monitoring Board for AstraZeneca.
Faculty/Planner
Ahmed Omar Kaseb, MD, CMQ
Endowed Professor and Director, Hepatocellular Carcinoma Program
Member, NCI Hepatobiliary Task Force
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Ahmed Omar Kaseb, MD, CMQ, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Adaptimmune Therapeutics and Polaris
Pharmaceuticals Inc.
Grant/Research Support from Adaptimmune Therapeutics; AstraZeneca;
Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Merck & Co., Inc.; and Polaris Pharmaceuticals
Inc.
Faculty/Planner
Amit Singal, MD, MS
Professor of Medicine
Willis C. Maddrey Chair in Liver Disease
Chief of Hepatology and Medical Director of the Liver Tumor Program
UT Southwestern Medical Center
Dallas, Texas
Amit Singal, MD, MS, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Boston
Scientific; Eisai Inc.; Exact Sciences Corporation; Exelixis, Inc.; FujiFilm
Medical; Genentech, Inc.; Glycotest, Inc.; GRAIL, Inc; and Universal
Diagnostics.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Blue Faery: The Adrienne Wilson Liver Cancer Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported by independent medical education grants from AstraZeneca, Eisai Inc., Exelixis, Inc., Merck & Co., Inc., and Novocure, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 7/2/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents
StartThis activity expired on July 1, 2024; credit is no longer available.
Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents
Activity Format: Internet Enduring Activity
Activity Release Date: June 2, 2023
Activity Expiration Date: July 1, 2024
Time to Complete Activity: 60 minutes
Program Overview
Elevated low-density lipoprotein cholesterol (LDL-C) levels are causally related to the risk of atherosclerotic cardiovascular disease (ASCVD)—justifying the guidance from multiple professional societies that emphasize the importance of lowering LDL-C to reduce cardiovascular risk. Despite the availability of nearly ten different classes of medications indicated to lower cholesterol levels, dyslipidemia is not appropriately managed for many patients, resulting in target LDL-C goals not being achieved. In this activity, based on a recent live symposium, experts discuss targeted therapies to optimize lipid management, including primary and secondary prevention of CV events, with PCSK9-targeting therapies (in particular, PCSK9 antibodies and novel small interfering RNAs).
Target Audience
This activity has been designed to meet the educational needs of cardiologists, internists, lipid specialists, nurses, pharmacists, and other clinicians involved in the management of hyperlipidemia.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Apply current hyperlipidemia treatment guidelines for primary and secondary prevention of cardiovascular events in patients with ASCVD
- Assess the efficacy and safety data for PCSK9-targeting therapies for hyperlipidemia management in patients with ASCVD risk enhancers
- Describe the mechanism of action and ability of PCSK9-targeting therapies to optimize treatment for high-risk ASCVD patients on maximally tolerated doses of statins or for statin-intolerant patients
Criteria for Success
Statements of credit will be awarded based on the participant’s attendance
and submission of the activity evaluation form. Partial credit may be awarded
for ACPE credit. A statement of credit will be available upon completion of
an online evaluation/claimed credit form at www.lipid.org/cme. The deadline
to claim credit is July 1, 2024.
For Pharmacists: Upon receipt of the completed activity evaluation
form, transcript information will be available at www.mycpemonitor.net within
4 weeks.
*IMPORTANT* Pharmacists MUST request credit before July 1, 2024. Credit
requested after this date will be subject to a fee by the accreditation
board.
Commercial Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Credit Designation
CME Credit Provided by the National Lipid Association
![]() |
In support of improving patient care, this activity has been planned and implemented by the National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physician Credit Designation Statement
The National Lipid Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CME Credit(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 CME CreditTM from organizations accredited by ACCME.
Pharmacists
This activity has been approved for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number – JA0007192-9999-23-007-H01-P (Knowledge).
Nursing
The maximum number of hours awarded for this CE activity is 1.0 contact
hours.
For the advanced practice nurse, pharmacotherapy hours will be calculated on
your certificate.
Faculty
Co-Chair & Presenter
P. Barton Duell, MD
Professor of Medicine
Director, Sterol Analysis Laboratory
Director, LDL Apheresis Unit
Oregon Health & Science University
Center for Preventive Cardiology
Knight Cardiovascular Institute
Division of Endocrinology, Diabetes and Clinical Nutrition
Portland, Oregon
P. Barton Duell, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Akcea Therapeutics, Inc./Ionis
Pharmaceuticals; Esperion Therapeutics, Inc.; Kaneka Medical America LLC;
Novo Nordisk Inc.; and Regeneron Pharmaceuticals Inc.
Grant/Research Support from Regeneron Pharmaceuticals Inc.;
REGENXBIO Inc.; and Retrophin/Travere Therapeutics, Inc.
Co-Chair & Presenter
Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC
Clinical Pharmacist
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon
Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC, has a financial
interest/relationship or affiliation in the form of:
Grant/Research Support from Akcea Pharmaceuticals.
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Disclosure of Unlabeled Use and Investigational Products
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclosure Declaration
It is the policy of the NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by the NLA prior to accreditation of the activity. The NLA planners and reviewers have no relevant financial relationships to disclose.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
Permissions
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.
Copyright © 2000-2023, PeerView
This activity expired on July 1, 2024; credit is no longer available.
Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents
Activity Format: Internet Enduring Activity
Activity Release Date: June 2, 2023
Activity Expiration Date: July 1, 2024
Time to Complete Activity: 60 minutes
Program Overview
Elevated low-density lipoprotein cholesterol (LDL-C) levels are causally related to the risk of atherosclerotic cardiovascular disease (ASCVD)—justifying the guidance from multiple professional societies that emphasize the importance of lowering LDL-C to reduce cardiovascular risk. Despite the availability of nearly ten different classes of medications indicated to lower cholesterol levels, dyslipidemia is not appropriately managed for many patients, resulting in target LDL-C goals not being achieved. In this activity, based on a recent live symposium, experts discuss targeted therapies to optimize lipid management, including primary and secondary prevention of CV events, with PCSK9-targeting therapies (in particular, PCSK9 antibodies and novel small interfering RNAs).
Target Audience
This activity has been designed to meet the educational needs of cardiologists, internists, lipid specialists, nurses, pharmacists, and other clinicians involved in the management of hyperlipidemia.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Apply current hyperlipidemia treatment guidelines for primary and secondary prevention of cardiovascular events in patients with ASCVD
- Assess the efficacy and safety data for PCSK9-targeting therapies for hyperlipidemia management in patients with ASCVD risk enhancers
- Describe the mechanism of action and ability of PCSK9-targeting therapies to optimize treatment for high-risk ASCVD patients on maximally tolerated doses of statins or for statin-intolerant patients
Criteria for Success
Statements of credit will be awarded based on the participant’s attendance
and submission of the activity evaluation form. Partial credit may be awarded
for ACPE credit. A statement of credit will be available upon completion of
an online evaluation/claimed credit form at www.lipid.org/cme. The deadline
to claim credit is July 1, 2024.
For Pharmacists: Upon receipt of the completed activity evaluation
form, transcript information will be available at www.mycpemonitor.net within
4 weeks.
*IMPORTANT* Pharmacists MUST request credit before July 1, 2024. Credit
requested after this date will be subject to a fee by the accreditation
board.
Commercial Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Credit Designation
CME Credit Provided by the National Lipid Association
![]() |
In support of improving patient care, this activity has been planned and implemented by the National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physician Credit Designation Statement
The National Lipid Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CME Credit(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 CME CreditTM from organizations accredited by ACCME.
Pharmacists
This activity has been approved for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number – JA0007192-9999-23-007-H01-P (Knowledge).
Nursing
The maximum number of hours awarded for this CE activity is 1.0 contact
hours.
For the advanced practice nurse, pharmacotherapy hours will be calculated on
your certificate.
Faculty
Co-Chair & Presenter
P. Barton Duell, MD
Professor of Medicine
Director, Sterol Analysis Laboratory
Director, LDL Apheresis Unit
Oregon Health & Science University
Center for Preventive Cardiology
Knight Cardiovascular Institute
Division of Endocrinology, Diabetes and Clinical Nutrition
Portland, Oregon
P. Barton Duell, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Akcea Therapeutics, Inc./Ionis
Pharmaceuticals; Esperion Therapeutics, Inc.; Kaneka Medical America LLC;
Novo Nordisk Inc.; and Regeneron Pharmaceuticals Inc.
Grant/Research Support from Regeneron Pharmaceuticals Inc.;
REGENXBIO Inc.; and Retrophin/Travere Therapeutics, Inc.
Co-Chair & Presenter
Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC
Clinical Pharmacist
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon
Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC, has a financial
interest/relationship or affiliation in the form of:
Grant/Research Support from Akcea Pharmaceuticals.
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Disclosure of Unlabeled Use and Investigational Products
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclosure Declaration
It is the policy of the NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by the NLA prior to accreditation of the activity. The NLA planners and reviewers have no relevant financial relationships to disclose.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
Permissions
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.
Copyright © 2000-2023, PeerView

Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition
StartThis activity expired on June 30, 2024; credit is no longer available.
Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition
Media: Enduring Material
Activity Release Date: June 1, 2023
Activity Expiration Date: June 30, 2024
Time to Complete Activity: 60 minutes
Activity Description
Optimal management of multiple sclerosis (MS) requires selecting
medications that safely and effectively target different aspects of
pathophysiology and offer choices in administration, risk/benefit balance,
and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an
emerging class of disease-modifying therapies that affect processes mediated
by B cells and myeloid cells, which are contributors to the inflammation and
neurodegeneration that drive MS. BTK inhibitors are a novel class in MS
management with four agents currently in phase 3 trials. As such, clinicians
must remain up to date with the latest data on the rationale for their use
and trial findings on the efficacy, safety, and tolerability of this
promising line of treatment.
At a recent PeerView live event, MS experts shared relevant stories from
their practice to highlight the rationale for the use of BTK inhibitors in
MS, as well as perspectives on potential applications in clinical care and
the latest data from clinical trials on BTK inhibition.
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other clinicians involved in the care of patients with multiple sclerosis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the rationale for investigating the potential of Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) treatment
- Assess emerging evidence on the risks and benefits associated with BTK inhibitors in late-stage clinical trials for the treatment of MS
- Identify patients who might be candidates for treatment with a BTK inhibitor, based on available data as well as individual patient characteristics and priorities
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Amit Bar-Or, MD, FRCPC
Melissa and Paul Anderson President’s Distinguished Chair
Professor, Department of Neurology
Chief, Division of Multiple Sclerosis and Related Disorders
Director, Centre for Neuroinflammation and Experimental Therapeutics
University of Pennsylvania
Children’s Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania
Amit Bar-Or, MD, FRCPC, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Accure Pharma; Atara Biotherapeutics,
Inc.; Biogen; Bristol Myers Squibb/Celgene Corporation/Receptos, Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Gossamer Bio; Janssen
Pharmaceuticals, Inc./Actelion Pharmaceuticals US, Inc.; Medimmune, LLC;
Merck & Co., Inc./EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; and
Sanofi Genzyme.
Grant/Research Support from Biogen; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Merck & Co., Inc./EMD Serono, Inc.; and Novartis
Pharmaceuticals Corporation (paid to institution).
Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada
Professor Anthony Traboulsee, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; F. Hoffmann-La
Roche Ltd; Genzyme Corporation; and Novartis Pharmaceuticals Canada
Inc.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Genzyme
Corporation.
Speaker for F. Hoffmann-La Roche Ltd and Genzyme
Corporation.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-014-H01-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on June 30, 2024; credit is no longer available.
Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition
Media: Enduring Material
Activity Release Date: June 1, 2023
Activity Expiration Date: June 30, 2024
Time to Complete Activity: 60 minutes
Activity Description
Optimal management of multiple sclerosis (MS) requires selecting
medications that safely and effectively target different aspects of
pathophysiology and offer choices in administration, risk/benefit balance,
and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an
emerging class of disease-modifying therapies that affect processes mediated
by B cells and myeloid cells, which are contributors to the inflammation and
neurodegeneration that drive MS. BTK inhibitors are a novel class in MS
management with four agents currently in phase 3 trials. As such, clinicians
must remain up to date with the latest data on the rationale for their use
and trial findings on the efficacy, safety, and tolerability of this
promising line of treatment.
At a recent PeerView live event, MS experts shared relevant stories from
their practice to highlight the rationale for the use of BTK inhibitors in
MS, as well as perspectives on potential applications in clinical care and
the latest data from clinical trials on BTK inhibition.
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other clinicians involved in the care of patients with multiple sclerosis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the rationale for investigating the potential of Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) treatment
- Assess emerging evidence on the risks and benefits associated with BTK inhibitors in late-stage clinical trials for the treatment of MS
- Identify patients who might be candidates for treatment with a BTK inhibitor, based on available data as well as individual patient characteristics and priorities
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Amit Bar-Or, MD, FRCPC
Melissa and Paul Anderson President’s Distinguished Chair
Professor, Department of Neurology
Chief, Division of Multiple Sclerosis and Related Disorders
Director, Centre for Neuroinflammation and Experimental Therapeutics
University of Pennsylvania
Children’s Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania
Amit Bar-Or, MD, FRCPC, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Accure Pharma; Atara Biotherapeutics,
Inc.; Biogen; Bristol Myers Squibb/Celgene Corporation/Receptos, Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Gossamer Bio; Janssen
Pharmaceuticals, Inc./Actelion Pharmaceuticals US, Inc.; Medimmune, LLC;
Merck & Co., Inc./EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; and
Sanofi Genzyme.
Grant/Research Support from Biogen; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Merck & Co., Inc./EMD Serono, Inc.; and Novartis
Pharmaceuticals Corporation (paid to institution).
Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada
Professor Anthony Traboulsee, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; F. Hoffmann-La
Roche Ltd; Genzyme Corporation; and Novartis Pharmaceuticals Canada
Inc.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Genzyme
Corporation.
Speaker for F. Hoffmann-La Roche Ltd and Genzyme
Corporation.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-014-H01-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView